Page last updated: 2024-12-08

regadenoson

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID219024
CHEMBL ID317052
CHEBI ID135613
SCHEMBL ID678893
MeSH IDM0495792

Synonyms (54)

Synonym
regadenoson monohydrate
CHEMBL317052 ,
regadenoson [usan:inn]
unii-7axv542lz4
7axv542lz4 ,
adenosine, 2-(4-((methylamino)carbonyl)-1h-pyrazol-1-yl)-
1-(6-amino-9-beta-d-ribofuranosyl-9h-purin-2-yl)-n-methyl-1h-pyrazole-4-carboxamide
(1-(9-(3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-6-aminopurin-2-yl)pyrazol-4-yl)-n-methylcarboxamide
cvt-3146
rapiscan
lexiscan
regadenoson
D05711
313348-27-5
lexiscan (tn)
regadenoson (usan/inn)
CHEBI:135613
cvt 3146
bdbm50119132
1-[6-amino-9-((2r,3r,4s,5r)-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-9h-purin-2-yl]-1h-pyrazole-4-carboxylic acid methylamide
2-[4-[(methylamino)carbonyl]-1h-pyrazol-1-yl]adenosine
regadenoson anhydrous
regadenoson [inn]
regadenoson [mi]
regadenoson [mart.]
S5358
gtpl5596
DB06213
SCHEMBL678893
6-amino-2-[4-(methylcarbamoyl)-1h-pyrazol-1-yl]purine-9-yl-beta-d-ribofuranoside;1-(6-amino-9-((2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yloxy)-9h-purin-2-yl)-n-methyl-1h-pyrazole-4-carboxamide
NCGC00249892-01
dtxsid4057712 ,
tox21_113668
dtxcid5031501
cas-313348-27-5
adenosine, 2-[4-[(methylamino)carbonyl]-1h-pyrazol-1-yl]-
AKOS026750593
HY-A0168
CS-5612
1-{6-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-9h-purin-2-yl}-n-methyl-1h-pyrazole-4-carboxamide
J-018384
EX-A2148
regadenoson; cvt-3146
(1-{9-[(4s,2r,3r,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-n-methylcarboxamide
LZPZPHGJDAGEJZ-AKAIJSEGSA-N
Q7307897
1-(6-amino-9-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9h-purin-2-yl)-n-methyl-1h-pyrazole-4-carboxamide
HMS3886O21
AMY27715
CCG-268525
AS-56292
EN300-19633972
AC-35838
BP-58629

Research Excerpts

Overview

Regadenoson is a well-tolerated vasodilator that can be safely employed for stress perfusion CMR, with high diagnostic performance. It is a safe drug for use in MPI with little, if any, side effects of major clinical significance.

ExcerptReferenceRelevance
"Regadenoson is a well-tolerated vasodilator that can be safely employed for stress perfusion CMR, with high diagnostic performance."( Safety, feasibility, and hemodynamic response of regadenoson for stress perfusion CMR.
Bastarrika, G; Caballeros, M; de la Fuente, A; Ezponda, A; Gavira, JJ; Muñiz-Sáenz-Diez, J, 2023
)
1.89
"Regadenoson is an adenosine A"( Daily Caffeine Consumption Is Associated with Decreased Incidence of Symptoms and Hemodynamic Changes During Pharmacologic Stress with Regadenoson.
Abidov, A; Harhash, AA; Huang, JJ; Kay, MD; Krupinski, EA; Kuo, PH; McMillan, NA; Posch, MI, 2020
)
2.2
"Regadenoson is a selective adenosine receptor agonist. "( Regadenoson versus dipyridamole: Evaluation of stress myocardial blood flow response on a CZT-SPECT camera.
Angoulvant, D; Bailly, M; Brana, Q; Courtehoux, M; Metrard, G; Ribeiro, MJ; Thibault, F, 2022
)
3.61
"Regadenoson is a safe drug for use in MPI with little, if any, side effects of major clinical significance."( Regadenoson administration and QT interval prolongation during pharmacological radionuclide myocardial perfusion imaging.
Afshar, M; Ashraf, U; Bella, JN; Chughtai, T; Kamalakkannan, G; Patel, Y; Rafiq, A; Raiszadeh, F; Sklyar, E,
)
2.3
"Regadenoson is an FDA approved adenosine receptor agonist which increases blood-brain barrier (BBB) permeability in rodents. "( The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study.
George, RT; Grossman, SA; Gujar, SK; Jackson, S; Lodge, MA; Piotrowski, A; Wahl, RL, 2017
)
2.26
"Regadenoson is a selective A"( Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review.
Doukky, R; Golzar, Y; Vij, A, 2018
)
3.37
"Regadenoson is a viable alternative to intravenous adenosine for achieving maximal hyperemia during FFR assessment. "( Use of regadenoson for measurement of fractional flow reserve.
Clavijo, LC; Doherty, R; Gopal, A; Matthews, RV; Mehra, A; Prasad, A; Shavelle, DM; Somma, K; Vora, H; Zareh, M, 2014
)
2.3
"Regadenoson is a selective adenosine A2A-receptor agonist, used as a pharmacological stress agent for myocardial perfusion imaging. "( Age and gender as predictors of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: a substudy of the ASSUAGE trial.
Demori, RM; Doukky, R; Rangel, MO,
)
1.79
"Regadenoson is a vasodilator stress agent that selectively activates the A2A receptor. "( Prognostic value of normal regadenoson stress perfusion cardiovascular magnetic resonance.
Bhave, NM; Cavanaugh, KP; Chandra, S; Czobor, P; Davidson, MH; Freed, BH; Lang, RM; Mor-Avi, V; Narang, A; Patel, AR; Tanaka, SM; Turner, KM; Zaran, ER, 2013
)
2.13
"Regadenoson is a recently approved selective adenosine-2A receptor agonist to induce pharmacological stress in myocardial perfusion imaging (MPI) procedures using a single bolus injection."( [Regadenoson as a new stress agent in myocardial perfusion imaging. Initial experience in The Netherlands].
Buiting, M; Jager, PL; Knollema, S; Mouden, M; Oostdijk, AH; Timmer, J,
)
2.48
"Regadenoson is a selective A2A receptor agonist approved for use as a pharmacologic stress agent for myocardial perfusion imaging after several multicenter trials demonstrated its equivalence in diagnostic accuracy for the detection of coronary artery disease and a decreased incidence of serious side effects as compared to adenosine. "( Asystole following regadenoson infusion in stable outpatients.
Cohen, M; Dunn, T; Mooney, D; Rosenblatt, J, 2014
)
2.17
"Regadenoson is a newer adenosine alternative administered as a single intravenous bolus during nuclear stress testing, but its efficacy and safety during FFR testing have been evaluated only in small, single-center studies."( Pooled comparison of regadenoson versus adenosine for measuring fractional flow reserve and coronary flow in the catheterization laboratory.
Angiolillo, DJ; Guzman, LA; Kennedy, KF; Lim, MJ; Morris, DL; Neumayr, RH; Shavelle, DM; Stolker, JM; Weber, E; Zareh, M; Zenni, MM,
)
1.17
"Regadenoson is a pharmacologic stress agent that has been widely adopted as an alternative over other pharmacologic vasodilator agents due to its ease of use, patient tolerance, and safety profile. "( ST Segment Elevation ECG Changes During Pharmacologic Stress With Regadenoson.
Bonyadlou, S; Huang, HW; Mehra, A; Qamruddin, S; Yoon, AJ, 2016
)
2.11
"Regadenoson is a selective A"( Safety and tolerability of intravenous regadenoson in healthy subjects: A randomized, repeat-dose, placebo-controlled study.
Desai, A; Kitt, TM; Kowalski, D; Rammelsberg, D; Simmons, N; Townsend, R, 2017
)
2.17
"Regadenoson is an adenosine A(2A) receptor agonist approved for use as a pharmacologic stress agent for radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. "( Regadenoson.
Curran, MP; Garnock-Jones, KP, 2010
)
3.25
"Regadenoson is a selective A(2A) receptor agonist that was recently approved by the Food and Drug Administration for vasodilator stress myocardial perfusion imaging. "( Safety of regadenoson in patients with end-stage renal disease.
Aljaroudi, W; Hage, F; Heo, J; Hermann, D; Iskandrian, AE, 2010
)
2.21
"Regadenoson is a pharmacologic stress agent, which was recently approved for stress myocardial perfusion imaging (MPI). "( Lessons from regadenoson and low-level treadmill/regadenoson myocardial perfusion imaging: initial clinical experience in 1263 patients.
Brunken, RC; Cerqueira, MD; Houghtaling, P; Jaber, WA; Kwon, DH; Lieber, E; Menon, V; Young, R, 2010
)
2.17
"Regadenoson is a selective A(2A) receptor agonist that is used for vasodilator stress myocardial perfusion imaging (MPI). "( Safety of regadenoson in patients with end-stage liver disease.
Aljaroudi, W; Bhambhvani, P; Heo, J; Iqbal, F; Iskandrian, AE; Koneru, J, 2011
)
2.21
"Regadenoson is a novel selective A2A adenosine receptor agonist, which is administered as an intravenous bolus at a fixed dose. "( Comparison of the myocardial blood flow response to regadenoson and dipyridamole: a quantitative analysis in patients referred for clinical 82Rb myocardial perfusion PET.
Bengel, FM; Bravo, P; Fukushima, K; Goudarzi, B; Merrill, J, 2011
)
2.06
"Regadenoson is a potentially useful vasodilator for stress MRI studies."( The effect of obesity on regadenoson-induced myocardial hyperemia: a quantitative magnetic resonance imaging study.
Adluru, G; Chen, L; DiBella, EV; Fluckiger, JU; Jiji, R; Kim, TH; Kuppahally, S; Litwin, SE; Matthews, B; McGann, C; Pack, NA; Priester, T, 2012
)
1.4
"Regadenoson is a coronary vasodilator that causes tachycardia via activation of the sympathetic nervous system. "( Selective action of metoprolol to attenuate regadenoson-induced tachycardia in conscious dogs.
Belardinelli, L; Hintze, TH; Ochoa, M; Shryock, JC; Xu, X; Zhang, S; Zhao, G, 2012
)
2.08
"Regadenoson (REG) is a A2a receptor selective pharmacologic SPECT imaging agent. "( Hemodynamic response, arrhythmic risk, and overall safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients.
Ananthasubramaniam, K; Cabrera, R; Dhanalakota, S; Husain, Z; Jacobsen, G; Karthikeyan, AS; Palani, G; Pathmanathan, S, 2012
)
2.06
"Regadenoson is a selective A 2A adenosine receptor agonist used when MPI with exercise is contraindicated."( Regadenoson.
Bengalorkar, GM; Bhuvana, K; Kumar, TN; Sarala, N,
)
2.3
"Regadenoson is a selective A2A adenosine receptor agonist and vasodilator used to increase the heterogeneity of distribution of coronary blood flow during myocardial perfusion imaging. "( Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans.
Belardinelli, L; Blackburn, B; Gordi, T; Kerensky, RA; Lieu, HD; Olmsted, AW; Shryock, JC; von Mering, GO, 2007
)
3.23

Effects

Regadenoson has demonstrated non-inferiority to adenosine for detecting reversible myocardial perfusion defects in phase 3 trials. Patients were more comfortable during the regadenosonson stress procedure than during an adenosinesine infusion. Regadenos on has advantages of a fixed dose and favorable symptom profile, but its mean maximal hyperemia is only 2.3 minutes.

ExcerptReferenceRelevance
"Regadenoson has demonstrated non-inferiority to adenosine for detecting reversible myocardial perfusion defects in phase 3 trials, and patients were more comfortable during the regadenoson stress procedure than during an adenosine infusion."( Advances in pharmacologic stress agents: focus on regadenoson.
Johnson, SG; Peters, S, 2010
)
1.34
"Regadenoson has advantages of a fixed dose and favorable symptom profile, but its mean maximal hyperemia is only 2.3 minutes."( Regadenoson pharmacologic rubidium-82 PET: a comparison of quantitative perfusion and function to dipyridamole.
Bateman, TM; Case, JA; Courter, SA; Cullom, SJ; McGhie, AI, 2013
)
2.55

Treatment

Regadenoson treatment (10 microg/kg) significantly (p < 0.05) increased plasma norepinephrine levels almost 2-fold above baseline.

ExcerptReferenceRelevance
"Regadenoson treatment during lung transplantation significantly reduced levels of MMP-9 (P < .05), but not MMP-2, and elevated levels of tissue inhibitor of metalloproteinase 1 (P < .05), an endogenous selective inhibitor of MMP-9. "( Regadenoson Reduces Soluble Receptor for Advanced Glycation End-Products in Lung Recipients.
Al-Suqi, M; Conaway, MR; Dhru, U; Fleischmann, E; Krupnick, AS; Lau, CL; Linden, J; Mostafa, E; Rabin, J; Zhao, Y, 2023
)
3.8
"Regadenoson treatment (10 microg/kg) significantly (p < 0.05) increased plasma norepinephrine levels almost 2-fold above baseline."( Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats.
Belardinelli, L; Biaggioni, I; Dhalla, AK; Wang, WQ; Wong, MY, 2006
)
1.06

Toxicity

Reversal of regadenoson with aminophylline is safe and equivalent to adenosine for FFR measurements.

ExcerptReferenceRelevance
" The most common adverse events with regadenoson were tachycardia (66%), dizziness (53%), headache (45%), and dyspnea (34%)."( Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial.
Barnes, PJ; Hansel, TT; Leaker, BR; Lieu, HD; Mathur, VS; Meng, L; O'Connor, B,
)
0.81
"In this pilot safety study of 48 patients with mild or moderate asthma who had bronchial reactivity to adenosine monophosphate, regadenoson was safe and well tolerated."( Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial.
Barnes, PJ; Hansel, TT; Leaker, BR; Lieu, HD; Mathur, VS; Meng, L; O'Connor, B,
)
0.74
"Previous reports have shown that a fixed unit bolus of regadenoson is safe and noninferior to adenosine for the detection of reversible perfusion defects by radionuclide imaging."( Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results.
Cerqueira, MD; Iskandrian, AE; Nguyen, P; Staehr, P; Underwood, SR, 2008
)
0.81
" We studied 277 consecutive patients with ESRD who had undergone regadenoson stress gated single photon emission computed tomography myocardial perfusion imaging and compared their side effect profile and safety outcome to those of 134 patients with normal kidney function."( Safety of regadenoson in patients with end-stage renal disease.
Aljaroudi, W; Hage, F; Heo, J; Hermann, D; Iskandrian, AE, 2010
)
1
" There were no deaths or medication-related adverse events that required hospitalization in either group within 30 days of the study."( Safety of regadenoson in patients with end-stage liver disease.
Aljaroudi, W; Bhambhvani, P; Heo, J; Iqbal, F; Iskandrian, AE; Koneru, J, 2011
)
0.77
"No major adverse events were noted immediately after REG-SPECT or at 1 week of follow-up."( Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis.
Ananthasubramaniam, K; Husain, Z; Karthikeyan, AS; Karthikeyan, V; Palani, G; Salinas, RC, 2011
)
0.77
"BMI does not alter the efficacy of regadenoson MPI despite lower PRC in high BMI subjects, or its side effect profile despite higher PRC in low BMI subjects."( Effect of body mass index on the efficacy, side effect profile, and plasma concentration of fixed-dose regadenoson for myocardial perfusion imaging.
Blackburn, B; Cerqueira, MD; Olmsted, A; Reyes, E; Staehr, P; Underwood, SR; Zeng, D, 2011
)
0.86
" Both vasodilators had similar side effect profiles (P = ."( Regadenoson is a safe and well-tolerated pharmacological stress agent for myocardial perfusion imaging in post-heart transplant patients.
Ananthasubramaniam, K; Barboza, J; Cavalcante, JL, 2011
)
1.81
" REG appears to be safe and well tolerated without significant cardiovascular adverse events."( Regadenoson is a safe and well-tolerated pharmacological stress agent for myocardial perfusion imaging in post-heart transplant patients.
Ananthasubramaniam, K; Barboza, J; Cavalcante, JL, 2011
)
1.81
" The side effect profile of Grp 1 was also compared to a historical cohort who underwent intravenous dipyridamole thallium-201 imaging and adenosine SPECT."( Hemodynamic response, arrhythmic risk, and overall safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients.
Ananthasubramaniam, K; Cabrera, R; Dhanalakota, S; Husain, Z; Jacobsen, G; Karthikeyan, AS; Palani, G; Pathmanathan, S, 2012
)
0.62
" The primary outcome measure was the frequency of serious adverse events over 24-h post-dose."( A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease.
Ananthasubramaniam, K; Bukofzer, S; Feaheny, K; Klauke, B; McNutt, B; Weiss, R, 2012
)
0.6
" No serious adverse events or deaths were reported over 24-h post-dose."( A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease.
Ananthasubramaniam, K; Bukofzer, S; Feaheny, K; Klauke, B; McNutt, B; Weiss, R, 2012
)
0.6
"Regadenoson was not associated with any serious or unexpected adverse events in subjects with stage 3 or 4 CKD."( A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease.
Ananthasubramaniam, K; Bukofzer, S; Feaheny, K; Klauke, B; McNutt, B; Weiss, R, 2012
)
2.05
"It is unknown whether the standardized intravenous aminophylline administration following regadenoson-stress can prevent the gastrointestinal and other adverse effects associated with regadenoson."( Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. "The ASSUAGE trial".
Calvin, JE; Doukky, R; Jain, S; Kiriakos, R; Morales Demori, R; Mwansa, V, 2012
)
0.86
"In a randomized, double-blinded, placebo-controlled clinical trial we compared the frequency and severity of regadenoson adverse effects in those who received 75 mg of intravenous aminophylline versus a matching placebo administered 2 minutes after regadenoson or 90 seconds post-radioisotope injection."( Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. "The ASSUAGE trial".
Calvin, JE; Doukky, R; Jain, S; Kiriakos, R; Morales Demori, R; Mwansa, V, 2012
)
0.86
" Additionally, aminophylline use was associated with 34% reduction in the secondary endpoint of any regadenoson adverse effects [55 (44."( Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. "The ASSUAGE trial".
Calvin, JE; Doukky, R; Jain, S; Kiriakos, R; Morales Demori, R; Mwansa, V, 2012
)
0.86
"This trial supports the routine administration of IV-aminophylline to reduce the frequency and severity of adverse effects associated with regadenoson-stress."( Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. "The ASSUAGE trial".
Calvin, JE; Doukky, R; Jain, S; Kiriakos, R; Morales Demori, R; Mwansa, V, 2012
)
0.85
" Dyspnea, the most frequent respiratory adverse event, occurred with higher incidence (P < ."( A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease.
Behm, S; Bukofzer, S; Feaheny, K; McNutt, BE; Prenner, BM, 2012
)
0.6
" Hemodynamics, side effects, and adverse events were entered prospectively into the database at the time of testing and were subsequently retrieved for analysis."( Safety and tolerability of regadenoson in 514 SPECT MPI patients with and without coronary artery disease and submaximal exercise heart rate response.
AlJaroudi, WA; Alraies, MC; Cerquiera, MD; Jaber, WA, 2013
)
0.69
" There was otherwise no significant difference in adverse events between different groups including those with and without CAD."( Safety and tolerability of regadenoson in 514 SPECT MPI patients with and without coronary artery disease and submaximal exercise heart rate response.
AlJaroudi, WA; Alraies, MC; Cerquiera, MD; Jaber, WA, 2013
)
0.69
"Among patients undergoing standard treadmill stress testing for MPI who do not reach THR, the administration of Reg at peak exercise is safe and without major adverse events."( Safety and tolerability of regadenoson in 514 SPECT MPI patients with and without coronary artery disease and submaximal exercise heart rate response.
AlJaroudi, WA; Alraies, MC; Cerquiera, MD; Jaber, WA, 2013
)
0.69
" The incidence of REG adverse effects and the hemodynamic and ECG responses to REG-stress were compared."( The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation.
Alqaid, A; Dick, R; Doukky, R; Morales Demori, R; Rangel, MO; Wassouf, M, 2013
)
0.68
" There was no significant difference in the incidence of the composite of any REG adverse effect [ESRD 108 (74%) vs control 73 (75%), P = ."( The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation.
Alqaid, A; Dick, R; Doukky, R; Morales Demori, R; Rangel, MO; Wassouf, M, 2013
)
0.68
" All stress protocols were well tolerated, and there were no significant adverse events."( Safety and feasibility of adjunctive regadenoson injection at peak exercise during exercise myocardial perfusion imaging: The Both Exercise and Regadenoson Stress Test (BERST) trial.
Aulwes, D; Gupta, D; Holly, TA; Montero, K; Ross, MI; Shen, S; Wilkins, JT; Wu, E, 2013
)
0.66
" Although there was no difference in the incidence of other adverse events, we observed a higher frequency in asthmatics of flushing, dry mouth, sweating and fatigue (1."( Comparative study of the safety of regadenoson between patients with mild/moderate chronic obstructive pulmonary disease and asthma.
Garcia, CS; Heffernan, AJ; Jimenez Heffernan, A; Lopez Martin, J; Ramos Font, C; Rivera de los Santos, F; Salgado Garcia, C; Sanchez de Mora, E; Ynfante Milá, I, 2014
)
0.68
"Knowledge of adverse events associated with regadenoson perfusion cardiac magnetic resonance (CMR) and patient tolerability has implications for patient safety and staff training."( Safety and tolerability of regadenoson CMR.
Arai, AE; Bandettini, WP; Leung, SW; Nguyen, KL; Shanbhag, S; Wilson, JR, 2014
)
0.96
" Symptoms and adverse events including death, myocardial infarction (MI), ventricular tachycardia (VT)/ventricular fibrillation (VF), hospitalization, arrhythmias, and haemodynamic stability were assessed."( Safety and tolerability of regadenoson CMR.
Arai, AE; Bandettini, WP; Leung, SW; Nguyen, KL; Shanbhag, S; Wilson, JR, 2014
)
0.7
" Notable adverse events included one case of bronchospasm and one case of heart failure exacerbation resulting in hospitalization."( Safety and tolerability of regadenoson CMR.
Arai, AE; Bandettini, WP; Leung, SW; Nguyen, KL; Shanbhag, S; Wilson, JR, 2014
)
0.7
"Regadenoson CMR is well tolerated and can be performed safely with few adverse events."( Safety and tolerability of regadenoson CMR.
Arai, AE; Bandettini, WP; Leung, SW; Nguyen, KL; Shanbhag, S; Wilson, JR, 2014
)
2.14
" Additional endpoints included major adverse cardiac events (MACE) and patient questionnaire responses."( Feasibility, safety and accuracy of regadenoson-atropine (REGAT) stress echocardiography for the diagnosis of coronary artery disease: an angiographic correlative study.
Alam, M; Ananthasubramaniam, K; Boedeker, S; Brooks, K; Iyer, H; Khandelwal, A; Nguyen, P; Saad, H; Shaikh, K; Wang, DD, 2014
)
0.68
" We assessed major adverse cardiac events and significant decreases in systolic blood pressure."( Stress positron emission tomography is safe and can guide coronary revascularization in high-risk patients being considered for transcatheter aortic valve replacement.
Cerqueira, MD; Cremer, PC; Jaber, WA; Khalaf, S; Lou, J; Rodriguez, L, 2014
)
0.4
" There were no major adverse events during testing."( Stress positron emission tomography is safe and can guide coronary revascularization in high-risk patients being considered for transcatheter aortic valve replacement.
Cerqueira, MD; Cremer, PC; Jaber, WA; Khalaf, S; Lou, J; Rodriguez, L, 2014
)
0.4
" Secondary endpoints included 12-lead electrocardiogram measurements, clinical laboratory evaluations (hematology, chemistry, and urinalysis), and adverse events."( Safety and tolerability of intravenous regadenoson in healthy subjects: A randomized, repeat-dose, placebo-controlled study.
Desai, A; Kitt, TM; Kowalski, D; Rammelsberg, D; Simmons, N; Townsend, R, 2017
)
0.72
"Repeated doses of regadenoson appeared to be safe and well tolerated in healthy subjects."( Safety and tolerability of intravenous regadenoson in healthy subjects: A randomized, repeat-dose, placebo-controlled study.
Desai, A; Kitt, TM; Kowalski, D; Rammelsberg, D; Simmons, N; Townsend, R, 2017
)
1.06
"To compare the adverse effect profiles of adenosine and regadenoson in patients undergoing outpatient cardiac stress testing."( Comparison of the Safety of Adenosine and Regadenoson in Patients Undergoing Outpatient Cardiac Stress Testing.
Brink, HL; Dickerson, JA; Pickworth, KK; Stephens, JA, 2015
)
0.93
" The primary outcome was the occurrence of adverse effects-arrhythmia, chest pain or tightness, dizziness, dyspnea, flushing, or headache, and use of the rescue agent aminophylline-in the adenosine and regadenoson groups."( Comparison of the Safety of Adenosine and Regadenoson in Patients Undergoing Outpatient Cardiac Stress Testing.
Brink, HL; Dickerson, JA; Pickworth, KK; Stephens, JA, 2015
)
0.87
"Among patients undergoing an outpatient pharmacologic stress test, the use of adenosine was associated with a lower occurrence of adverse effects and lower rate of a rescue agent use and may provide a potential medication cost savings opportunity compared with regadenoson."( Comparison of the Safety of Adenosine and Regadenoson in Patients Undergoing Outpatient Cardiac Stress Testing.
Brink, HL; Dickerson, JA; Pickworth, KK; Stephens, JA, 2015
)
0.86
" Hemodynamic variables and severity of adverse events (AE) were recorded before, during, and after administration."( Safety and tolerability of regadenoson for myocardial perfusion imaging - first Danish experience.
Aarøe, J; Eggert Jensen, S; Pape, M; Petersen, LJ; Zacho, HD, 2016
)
0.73
" Demographics, medical history, lung medications, adverse events, oxygen saturation (SatO2), MPI findings for coronary artery disease (CAD), and changes in systolic blood pressure (SBP), and heart rate (HR) were registered."( Safety of regadenoson in patients with severe chronic obstructive pulmonary disease.
Aroui, T; Jimenez-Heffernan, A; Lopez-Aguilar, R; Lopez-Martin, J; Ramos-Font, C; Rivera-de-Los-Santos, F; Ruiz-Frutos, C; Salgado-Garcia, C; Sanchez-de-Mora, E,
)
0.53
"The observed adverse event profile of regadenoson was similar to that of patients with mild-moderate COPD."( Safety of regadenoson in patients with severe chronic obstructive pulmonary disease.
Aroui, T; Jimenez-Heffernan, A; Lopez-Aguilar, R; Lopez-Martin, J; Ramos-Font, C; Rivera-de-Los-Santos, F; Ruiz-Frutos, C; Salgado-Garcia, C; Sanchez-de-Mora, E,
)
0.8
"Regadenoson combined with low-level exercise is safe and well tolerated in stable patients with severe COPD undergoing MPI."( Safety of regadenoson in patients with severe chronic obstructive pulmonary disease.
Aroui, T; Jimenez-Heffernan, A; Lopez-Aguilar, R; Lopez-Martin, J; Ramos-Font, C; Rivera-de-Los-Santos, F; Ruiz-Frutos, C; Salgado-Garcia, C; Sanchez-de-Mora, E,
)
1.98
" Regadenoson can potentially have an adverse impact due to their tenuous hemodynamics."( Safety of regadenoson stress testing in patients with pulmonary hypertension.
Cascino, T; Corbett, JR; Ficaro, EP; Ghannam, M; Konerman, M; Lazarus, JJ; McLaughlin, VV; Mikhova, K; Moles, VM; Murthy, VL; Saleh, A; Weinberg, RL; Yun, HJ, 2018
)
1.79
"Regadenoson stress MPI appears to be well tolerated and safe in patients with PH."( Safety of regadenoson stress testing in patients with pulmonary hypertension.
Cascino, T; Corbett, JR; Ficaro, EP; Ghannam, M; Konerman, M; Lazarus, JJ; McLaughlin, VV; Mikhova, K; Moles, VM; Murthy, VL; Saleh, A; Weinberg, RL; Yun, HJ, 2018
)
2.33
"To compare the frequency of adverse events in patients undergoing myocardial perfusion imaging (MPI) with either regadenoson or dipyridamole."( Regadenoson versus Dipyridamole: A Comparison of the Frequency of Adverse Events in Patients Undergoing Myocardial Perfusion Imaging.
Amer, KA; Cohen, G; Edwin, SB; Hurren, JR, 2017
)
2.11
" The primary endpoint was the composite occurrence of any documented adverse event in each group."( Regadenoson versus Dipyridamole: A Comparison of the Frequency of Adverse Events in Patients Undergoing Myocardial Perfusion Imaging.
Amer, KA; Cohen, G; Edwin, SB; Hurren, JR, 2017
)
1.9
"Dipyridamole was associated with fewer adverse events than regadenoson in patients undergoing MPI."( Regadenoson versus Dipyridamole: A Comparison of the Frequency of Adverse Events in Patients Undergoing Myocardial Perfusion Imaging.
Amer, KA; Cohen, G; Edwin, SB; Hurren, JR, 2017
)
2.14
"Regadenoson in combination with low-level exercise is safe and well tolerated over a wide range of BMI, with TE exercise showing a better side effect profile than SS."( Influence of body mass index and type of low-level exercise on the side effect profile of regadenoson.
Aroui, T; Jimenez-Heffernan, A; Lopez-Martin, J; Molina-Mora, M; Ramos-Font, C; Rivera de Los Santos, F; Ruiz-Frutos, C; Salgado-Garcia, C; Sanchez de Mora, E, 2017
)
2.12
"AIMThe study aims to test whether simultaneous measurement of fractional flow reserve (FFR), coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) is feasible, safe and effective during regadenoson-induced hyperemia."( Feasibility, safety and effectiveness in measuring microvascular resistance with regadenoson.
Bönner, F; Heimann, M; Jung, C; Kelm, M; Lachmann, V; Verde, PE; Zeus, T, 2019
)
0.93
"Reversal of regadenoson with aminophylline is safe and equivalent to adenosine for FFR measurements."( Intravenous regadenoson with aminophylline reversal is safe and equivalent to intravenous adenosine infusion for fractional flow reserve measurements.
Bober, R; Edward, JA; Lee, JH; Morin, DP; White, CJ, 2018
)
1.24
" Medical records were reviewed to determine hemodynamic and ECG response to regadenoson and to identify adverse reactions."( Safety of regadenoson positron emission tomography stress testing in orthotopic heart transplant patients.
Aaronson, K; Colvin, M; Corbett, JR; Ghannam, M; Koelling, T; Konerman, MC; Lazarus, JJ; Murthy, VL; Pagani, F; Saleh, A; Weinberg, RL, 2020
)
1.19
"No serious adverse events occurred."( Safety of regadenoson positron emission tomography stress testing in orthotopic heart transplant patients.
Aaronson, K; Colvin, M; Corbett, JR; Ghannam, M; Koelling, T; Konerman, MC; Lazarus, JJ; Murthy, VL; Pagani, F; Saleh, A; Weinberg, RL, 2020
)
0.96
"Regadenoson stress testing appears to be well tolerated and safe in OHT patients."( Safety of regadenoson positron emission tomography stress testing in orthotopic heart transplant patients.
Aaronson, K; Colvin, M; Corbett, JR; Ghannam, M; Koelling, T; Konerman, MC; Lazarus, JJ; Murthy, VL; Pagani, F; Saleh, A; Weinberg, RL, 2020
)
2.4
"To evaluate the safety, we assessed adverse effects in a retrospective matched cohort study of consecutive heart transplant recipients who underwent regadenoson stress CMR matched in a 2:1 ratio to age- and gender-matched non-heart transplant patients."( Safety and prognostic value of regadenoson stress cardiovascular magnetic resonance imaging in heart transplant recipients.
Akçakaya, M; Chen, KA; Farzaneh-Far, A; Hughes, A; Kazmirczak, F; Martin, CM; Nijjar, PS; Okasha, O; Shenoy, C; Zhang, L, 2019
)
1
" There were no differences in the rates of adverse effects between heart transplant recipients and non-heart transplant patients."( Safety and prognostic value of regadenoson stress cardiovascular magnetic resonance imaging in heart transplant recipients.
Akçakaya, M; Chen, KA; Farzaneh-Far, A; Hughes, A; Kazmirczak, F; Martin, CM; Nijjar, PS; Okasha, O; Shenoy, C; Zhang, L, 2019
)
0.8
"Regadenoson stress CMR is safe and well tolerated in heart transplant recipients, with no incidence of sinus node dysfunction or high-degree atrioventricular block, including in the first two years after heart transplantation."( Safety and prognostic value of regadenoson stress cardiovascular magnetic resonance imaging in heart transplant recipients.
Akçakaya, M; Chen, KA; Farzaneh-Far, A; Hughes, A; Kazmirczak, F; Martin, CM; Nijjar, PS; Okasha, O; Shenoy, C; Zhang, L, 2019
)
2.24
" We recorded cardiovascular risk factors, medications, and indications for the test as well as vital signs at rest and under stress and the symptoms and adverse effects induced by the drug."( Safety of regadenoson for vasodilation in cardiac MRI stress tests.
Baizan, AG; Bastarrika, G; Caballeros, M; Calvo, M; Ezponda, A; Gavira, JJ; Pueyo, JC,
)
0.53
" No severe adverse effects were observed."( Safety of regadenoson for vasodilation in cardiac MRI stress tests.
Baizan, AG; Bastarrika, G; Caballeros, M; Calvo, M; Ezponda, A; Gavira, JJ; Pueyo, JC,
)
0.53
"Patient experience and safety were similar between CT-MPI and SPECT procedures and no serious adverse events due to the administration of regadenoson occurred."( The Feasibility, Tolerability, Safety, and Accuracy of Low-radiation Dynamic Computed Tomography Myocardial Perfusion Imaging With Regadenoson Compared With Single-photon Emission Computed Tomography.
Bayer, RR; De Cecco, CN; Duguay, TM; Jacobs, BE; Johnson, AA; Litwin, SE; Nance, JW; Schoepf, UJ; Suranyi, P; Tesche, C; van Assen, M; Varga-Szemes, A, 2021
)
1.03
" All side effects and adverse events were recorded."( Safety of regadenoson with theophylline reversal during dynamic computed tomography perfusion and magnetic resonance imaging in patients with coronary artery disease.
Demkow, M; Kępka, C; Kruk, M; Marczak, M; Miłosz-Wieczorek, B; Oleksiak, A; Śpiewak, M, 2020
)
0.96
"Regadenoson may be a safe vasodilator for CTP and MR MPI in patients with CAD."( Safety of regadenoson with theophylline reversal during dynamic computed tomography perfusion and magnetic resonance imaging in patients with coronary artery disease.
Demkow, M; Kępka, C; Kruk, M; Marczak, M; Miłosz-Wieczorek, B; Oleksiak, A; Śpiewak, M, 2020
)
2.4
" This study aims to identify any potential benefits of regadenoson, regarding the frequency of adverse reactions and its tolerability, over dipyridamole."( Safety and tolerability of regadenoson compared with dipyridamole in myocardial perfusion imaging in patients scheduled to undergo medium to high-risk noncardiac surgery: a randomized controlled study.
Datseris, I; Giannopoulou, C; Manolis, AS; Mourouzis, I; Pantos, K; Polytarchou, K; Stavrou, PZ, 2022
)
1.27
"A greater proportion of adverse reactions was recorded in the regadenoson group as compared to the dipyridamole group (53 vs."( Safety and tolerability of regadenoson compared with dipyridamole in myocardial perfusion imaging in patients scheduled to undergo medium to high-risk noncardiac surgery: a randomized controlled study.
Datseris, I; Giannopoulou, C; Manolis, AS; Mourouzis, I; Pantos, K; Polytarchou, K; Stavrou, PZ, 2022
)
1.26
"In our group of patients scheduled for myocardial perfusion imaging for preoperative assessment, the two agents, regadenoson and dipyridamole, have no significant differences in the frequency of mild adverse reactions and in aminophylline use, with regadenoson also having the advantage of faster symptom resolution."( Safety and tolerability of regadenoson compared with dipyridamole in myocardial perfusion imaging in patients scheduled to undergo medium to high-risk noncardiac surgery: a randomized controlled study.
Datseris, I; Giannopoulou, C; Manolis, AS; Mourouzis, I; Pantos, K; Polytarchou, K; Stavrou, PZ, 2022
)
1.23
"Utilizing electronic medical records at the University of Colorado hospital, we identified patients ≥ 18 years of age who had a pharmacologic stress test using regadenoson during periods of aminophylline shortage (3/1/2013 to 5/31/2013 and 4/1/2018 to 8/30/2018) in which theophylline was used as an alternative antidote for side effect reversal."( Safety and efficacy of IV theophylline for regadenoson-associated side effect reversal.
Page, RL; Pham, VA; Quaife, RA; Raines, J; Shakowski, C, 2023
)
1.37
" No adverse effects or events were reported."( Safety and efficacy of IV theophylline for regadenoson-associated side effect reversal.
Page, RL; Pham, VA; Quaife, RA; Raines, J; Shakowski, C, 2023
)
1.17
"Due to limited availability of aminophylline, theophylline may be a safe and effective alternative to reverse regadenoson-associated side effects."( Safety and efficacy of IV theophylline for regadenoson-associated side effect reversal.
Page, RL; Pham, VA; Quaife, RA; Raines, J; Shakowski, C, 2023
)
1.38
" Adverse events, clinical symptoms, and hemodynamic response were assessed."( Safety, feasibility, and hemodynamic response of regadenoson for stress perfusion CMR.
Bastarrika, G; Caballeros, M; de la Fuente, A; Ezponda, A; Gavira, JJ; Muñiz-Sáenz-Diez, J, 2023
)
1.16

Pharmacokinetics

The population pharmacokinetic model was developed to describe the pharmacokinetics of regadenoson in these subjects. Following intravenous bolus dose administration, regadene was rapidly distributed throughout the body, followed by relatively slower elimination.

ExcerptReferenceRelevance
" Heart rate and blood pressure were recorded at many of the same timepoints that the samples for the pharmacokinetic analysis were taken."( A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
Belardinelli, L; Frohna, P; Gordi, T; Lieu, H; Sun, HL; Wolff, A, 2006
)
0.58
" Following intravenous bolus dose administration, regadenoson was rapidly distributed throughout the body, followed by relatively slower elimination (terminal elimination half-life of approximately 2 hours)."( A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
Belardinelli, L; Frohna, P; Gordi, T; Lieu, H; Sun, HL; Wolff, A, 2006
)
0.83
" A population pharmacokinetic model was developed to describe the pharmacokinetics of regadenoson in these subjects."( Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function.
Blackburn, B; Gordi, T; Lieu, H, 2007
)
2.01

Compound-Compound Interactions

Of 1,764 consecutive patients, 1,581 (90%) received regadenoson combined with submaximal exercise unless contraindicated. The drug was well tolerated, notably also in patients with asthma or COPD.

ExcerptReferenceRelevance
"Of 1,764 consecutive patients, 1,581 (90%) received regadenoson combined with submaximal exercise unless contraindicated."( Regadenoson in Europe: first-year experience of regadenoson stress combined with submaximal exercise in patients undergoing myocardial perfusion scintigraphy.
Brinkert, M; Latus, K; Maenhout, A; Mizumoto, R; Nkomo, C; Reyes, E; Standbridge, K; Underwood, SR; Walker, S; Wechalekar, K, 2014
)
2.1
" Regadenoson combined with submaximal exercise was well tolerated, notably also in patients with asthma or COPD."( Regadenoson in Europe: first-year experience of regadenoson stress combined with submaximal exercise in patients undergoing myocardial perfusion scintigraphy.
Brinkert, M; Latus, K; Maenhout, A; Mizumoto, R; Nkomo, C; Reyes, E; Standbridge, K; Underwood, SR; Walker, S; Wechalekar, K, 2014
)
2.76

Dosage Studied

ExcerptRelevanceReference
" As regadenoson dosing is not dependent on patient weight or renal impairment and can be administered by rapid injection, it has the potential to simplify the stress procedure, reduce costs, and streamline the working day for the staff of the nuclear medicine department."( Advances in pharmacologic stress agents: focus on regadenoson.
Johnson, SG; Peters, S, 2010
)
1.17
" It is currently not clear if the absolute flow increase in response to this fixed dose is a function of distribution volume in individual patients or if it is generally comparable to the previous standard agents dipyridamole or adenosine, which are dosed based on weight."( Comparison of the myocardial blood flow response to regadenoson and dipyridamole: a quantitative analysis in patients referred for clinical 82Rb myocardial perfusion PET.
Bengel, FM; Bravo, P; Fukushima, K; Goudarzi, B; Merrill, J, 2011
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
purine nucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Purinergic signaling053

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency5.17730.001530.607315,848.9004AID1224841; AID1224842; AID1259401
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency0.53080.001024.504861.6448AID743215
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.00120.023723.228263.5986AID743223
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 1AHomo sapiens (human)Ki1,269.00000.00010.532610.0000AID34679
Adenosine receptor A3Homo sapiens (human)Ki6.67000.00000.930610.0000AID1138018; AID238913; AID33508
Adenosine receptor A2aHomo sapiens (human)Ki181.79370.00001.06099.7920AID1138011; AID1201434; AID1556655; AID238932; AID34679; AID34853; AID647885
Adenosine receptor A1Homo sapiens (human)Ki5,493.41000.00020.931610.0000AID1138015; AID1556656; AID30784
Adenosine receptor A2aRattus norvegicus (Norway rat)Ki0.29000.00021.494010.0000AID33011
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A2bHomo sapiens (human)EC50 (µMol)10.00000.00030.946110.0000AID1138014
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (119)

Processvia Protein(s)Taxonomy
behavioral fear response5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
gamma-aminobutyric acid signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of serotonin secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of vasoconstriction5-hydroxytryptamine receptor 1AHomo sapiens (human)
exploration behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of dopamine metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of hormone secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1AHomo sapiens (human)
inflammatory responseAdenosine receptor A3Homo sapiens (human)
signal transductionAdenosine receptor A3Homo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A3Homo sapiens (human)
regulation of heart contractionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A3Homo sapiens (human)
response to woundingAdenosine receptor A3Homo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell migrationAdenosine receptor A3Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityAdenosine receptor A3Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A3Homo sapiens (human)
synaptic transmission, dopaminergicAdenosine receptor A2aHomo sapiens (human)
response to amphetamineAdenosine receptor A2aHomo sapiens (human)
regulation of DNA-templated transcriptionAdenosine receptor A2aHomo sapiens (human)
phagocytosisAdenosine receptor A2aHomo sapiens (human)
apoptotic processAdenosine receptor A2aHomo sapiens (human)
inflammatory responseAdenosine receptor A2aHomo sapiens (human)
cellular defense responseAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
cell-cell signalingAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, cholinergicAdenosine receptor A2aHomo sapiens (human)
central nervous system developmentAdenosine receptor A2aHomo sapiens (human)
blood coagulationAdenosine receptor A2aHomo sapiens (human)
sensory perceptionAdenosine receptor A2aHomo sapiens (human)
locomotory behaviorAdenosine receptor A2aHomo sapiens (human)
blood circulationAdenosine receptor A2aHomo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A2aHomo sapiens (human)
response to xenobiotic stimulusAdenosine receptor A2aHomo sapiens (human)
response to inorganic substanceAdenosine receptor A2aHomo sapiens (human)
positive regulation of glutamate secretionAdenosine receptor A2aHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionAdenosine receptor A2aHomo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A2aHomo sapiens (human)
response to purine-containing compoundAdenosine receptor A2aHomo sapiens (human)
response to caffeineAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
positive regulation of urine volumeAdenosine receptor A2aHomo sapiens (human)
vasodilationAdenosine receptor A2aHomo sapiens (human)
eating behaviorAdenosine receptor A2aHomo sapiens (human)
negative regulation of vascular permeabilityAdenosine receptor A2aHomo sapiens (human)
negative regulation of neuron apoptotic processAdenosine receptor A2aHomo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleepAdenosine receptor A2aHomo sapiens (human)
negative regulation of alpha-beta T cell activationAdenosine receptor A2aHomo sapiens (human)
astrocyte activationAdenosine receptor A2aHomo sapiens (human)
neuron projection morphogenesisAdenosine receptor A2aHomo sapiens (human)
positive regulation of protein secretionAdenosine receptor A2aHomo sapiens (human)
negative regulation of inflammatory responseAdenosine receptor A2aHomo sapiens (human)
regulation of mitochondrial membrane potentialAdenosine receptor A2aHomo sapiens (human)
membrane depolarizationAdenosine receptor A2aHomo sapiens (human)
regulation of calcium ion transportAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
inhibitory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
prepulse inhibitionAdenosine receptor A2aHomo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2aHomo sapiens (human)
positive regulation of long-term synaptic potentiationAdenosine receptor A2aHomo sapiens (human)
positive regulation of apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
positive regulation of chronic inflammatory response to non-antigenic stimulusAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A2bHomo sapiens (human)
positive regulation of vascular endothelial growth factor productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
positive regulation of chemokine productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of interleukin-6 productionAdenosine receptor A2bHomo sapiens (human)
mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
positive regulation of mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
relaxation of vascular associated smooth muscleAdenosine receptor A2bHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2bHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
vasodilationAdenosine receptor A2bHomo sapiens (human)
temperature homeostasisAdenosine receptor A1Homo sapiens (human)
response to hypoxiaAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of respiratory gaseous exchange by nervous system processAdenosine receptor A1Homo sapiens (human)
negative regulation of acute inflammatory responseAdenosine receptor A1Homo sapiens (human)
negative regulation of leukocyte migrationAdenosine receptor A1Homo sapiens (human)
positive regulation of peptide secretionAdenosine receptor A1Homo sapiens (human)
positive regulation of systemic arterial blood pressureAdenosine receptor A1Homo sapiens (human)
negative regulation of systemic arterial blood pressureAdenosine receptor A1Homo sapiens (human)
regulation of glomerular filtrationAdenosine receptor A1Homo sapiens (human)
protein targeting to membraneAdenosine receptor A1Homo sapiens (human)
phagocytosisAdenosine receptor A1Homo sapiens (human)
inflammatory responseAdenosine receptor A1Homo sapiens (human)
signal transductionAdenosine receptor A1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
cell-cell signalingAdenosine receptor A1Homo sapiens (human)
nervous system developmentAdenosine receptor A1Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A1Homo sapiens (human)
response to inorganic substanceAdenosine receptor A1Homo sapiens (human)
negative regulation of glutamate secretionAdenosine receptor A1Homo sapiens (human)
response to purine-containing compoundAdenosine receptor A1Homo sapiens (human)
lipid catabolic processAdenosine receptor A1Homo sapiens (human)
negative regulation of synaptic transmission, GABAergicAdenosine receptor A1Homo sapiens (human)
positive regulation of nucleoside transportAdenosine receptor A1Homo sapiens (human)
negative regulation of neurotrophin productionAdenosine receptor A1Homo sapiens (human)
positive regulation of protein dephosphorylationAdenosine receptor A1Homo sapiens (human)
vasodilationAdenosine receptor A1Homo sapiens (human)
negative regulation of circadian sleep/wake cycle, non-REM sleepAdenosine receptor A1Homo sapiens (human)
negative regulation of apoptotic processAdenosine receptor A1Homo sapiens (human)
positive regulation of potassium ion transportAdenosine receptor A1Homo sapiens (human)
positive regulation of MAPK cascadeAdenosine receptor A1Homo sapiens (human)
negative regulation of hormone secretionAdenosine receptor A1Homo sapiens (human)
cognitionAdenosine receptor A1Homo sapiens (human)
leukocyte migrationAdenosine receptor A1Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of painAdenosine receptor A1Homo sapiens (human)
negative regulation of lipid catabolic processAdenosine receptor A1Homo sapiens (human)
positive regulation of lipid catabolic processAdenosine receptor A1Homo sapiens (human)
regulation of sensory perception of painAdenosine receptor A1Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergicAdenosine receptor A1Homo sapiens (human)
fatty acid homeostasisAdenosine receptor A1Homo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A1Homo sapiens (human)
long-term synaptic depressionAdenosine receptor A1Homo sapiens (human)
mucus secretionAdenosine receptor A1Homo sapiens (human)
negative regulation of mucus secretionAdenosine receptor A1Homo sapiens (human)
triglyceride homeostasisAdenosine receptor A1Homo sapiens (human)
regulation of cardiac muscle cell contractionAdenosine receptor A1Homo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationAdenosine receptor A1Homo sapiens (human)
negative regulation of long-term synaptic potentiationAdenosine receptor A1Homo sapiens (human)
negative regulation of long-term synaptic depressionAdenosine receptor A1Homo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
receptor-receptor interaction5-hydroxytryptamine receptor 1AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aHomo sapiens (human)
protein bindingAdenosine receptor A2aHomo sapiens (human)
calmodulin bindingAdenosine receptor A2aHomo sapiens (human)
lipid bindingAdenosine receptor A2aHomo sapiens (human)
enzyme bindingAdenosine receptor A2aHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingAdenosine receptor A2aHomo sapiens (human)
identical protein bindingAdenosine receptor A2aHomo sapiens (human)
protein-containing complex bindingAdenosine receptor A2aHomo sapiens (human)
alpha-actinin bindingAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2bHomo sapiens (human)
protein bindingAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor activityAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor bindingAdenosine receptor A1Homo sapiens (human)
purine nucleoside bindingAdenosine receptor A1Homo sapiens (human)
protein bindingAdenosine receptor A1Homo sapiens (human)
heat shock protein bindingAdenosine receptor A1Homo sapiens (human)
G-protein beta/gamma-subunit complex bindingAdenosine receptor A1Homo sapiens (human)
heterotrimeric G-protein bindingAdenosine receptor A1Homo sapiens (human)
protein heterodimerization activityAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
presynaptic membraneAdenosine receptor A3Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A3Homo sapiens (human)
dendriteAdenosine receptor A3Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
synapseAdenosine receptor A3Homo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
intermediate filamentAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
membraneAdenosine receptor A2aHomo sapiens (human)
dendriteAdenosine receptor A2aHomo sapiens (human)
axolemmaAdenosine receptor A2aHomo sapiens (human)
asymmetric synapseAdenosine receptor A2aHomo sapiens (human)
presynaptic membraneAdenosine receptor A2aHomo sapiens (human)
neuronal cell bodyAdenosine receptor A2aHomo sapiens (human)
postsynaptic membraneAdenosine receptor A2aHomo sapiens (human)
presynaptic active zoneAdenosine receptor A2aHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A2bHomo sapiens (human)
presynapseAdenosine receptor A2bHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2bHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
plasma membraneAdenosine receptor A1Homo sapiens (human)
plasma membraneAdenosine receptor A1Homo sapiens (human)
basolateral plasma membraneAdenosine receptor A1Homo sapiens (human)
axolemmaAdenosine receptor A1Homo sapiens (human)
asymmetric synapseAdenosine receptor A1Homo sapiens (human)
presynaptic membraneAdenosine receptor A1Homo sapiens (human)
neuronal cell bodyAdenosine receptor A1Homo sapiens (human)
terminal boutonAdenosine receptor A1Homo sapiens (human)
dendritic spineAdenosine receptor A1Homo sapiens (human)
calyx of HeldAdenosine receptor A1Homo sapiens (human)
postsynaptic membraneAdenosine receptor A1Homo sapiens (human)
presynaptic active zoneAdenosine receptor A1Homo sapiens (human)
synapseAdenosine receptor A1Homo sapiens (human)
dendriteAdenosine receptor A1Homo sapiens (human)
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (56)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1138020Selectivity ratio of Ki for human recombinant adenosine A1 receptor to Ki for human recombinant adenosine receptor A2a2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Adenosine A2A receptor as a drug discovery target.
AID1556656Displacement of [3H]CPX from human adenosine receptor A1 expressed in CHO-K1 cell membranes incubated for 2 hrs by radioligand competitive binding analysis2019European journal of medicinal chemistry, Oct-01, Volume: 179Design, synthesis and biological evaluation of 2-hydrazinyladenosine derivatives as A
AID1201434Binding affinity to human adenosine A2A receptor2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Design, synthesis, and biological evaluation of novel 2-((2-(4-(substituted)phenylpiperazin-1-yl)ethyl)amino)-5'-N-ethylcarboxamidoadenosines as potent and selective agonists of the A2A adenosine receptor.
AID33011Receptor binding affinity for the adenosine A2A receptor was determined using [3H]ZM-241385 as a radioligand in rat2002Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20
Structure-affinity relationships of the affinity of 2-pyrazolyl adenosine analogues for the adenosine A2A receptor.
AID238913Displacement of [125I]-AB MECA from recombinant human adenosine A3 receptor expressed in HEK cells2004Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19
2-Pyrazolyl-N(6)-substituted adenosine derivatives as high affinity and selective adenosine A(3) receptor agonists.
AID1138015Binding affinity to human recombinant adenosine A1 receptor2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Adenosine A2A receptor as a drug discovery target.
AID1138036Selectivity ratio of Ki for human recombinant adenosine receptor A2b to Ki for human recombinant adenosine receptor A2a2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Adenosine A2A receptor as a drug discovery target.
AID647885Binding affinity to A2A adenosine receptor2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A₂A adenosine receptor.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID238932Displacement of [3H]CGS-21680 from recombinant human adenosine A2a receptor expressed in HEK cells2004Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19
2-Pyrazolyl-N(6)-substituted adenosine derivatives as high affinity and selective adenosine A(3) receptor agonists.
AID30784Binding affinity for adenosine (ADO) A1 receptor in CHO cells2002Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20
Structure-affinity relationships of the affinity of 2-pyrazolyl adenosine analogues for the adenosine A2A receptor.
AID34853Receptor binding affinity for the adenosine A2A receptor were determined using [3H]ZM-241385 as a radioligand in pig2002Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20
Structure-affinity relationships of the affinity of 2-pyrazolyl adenosine analogues for the adenosine A2A receptor.
AID1556653Selectivity index, ratio of Ki for human adenosine receptor A1 expressed in CHO-K1 cell membrane to Ki for human adenosine receptor A2A expressed in HEK293 cell membrane incubated for 2 hrs by radioligand competitive binding analysis2019European journal of medicinal chemistry, Oct-01, Volume: 179Design, synthesis and biological evaluation of 2-hydrazinyladenosine derivatives as A
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1138039Selectivity ratio of Ki for human recombinant adenosine A3 receptor to Ki for human recombinant adenosine receptor A2a2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Adenosine A2A receptor as a drug discovery target.
AID34679Binding affinity for Adenosine A2A receptor in HEK cells2002Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20
Structure-affinity relationships of the affinity of 2-pyrazolyl adenosine analogues for the adenosine A2A receptor.
AID1138011Binding affinity to human recombinant adenosine receptor A2a2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Adenosine A2A receptor as a drug discovery target.
AID1556655Displacement of [3H]ZM241385 from human adenosine receptor A2A expressed in HEK-293 cell membrane incubated for 2 hrs by radioligand competitive binding analysis2019European journal of medicinal chemistry, Oct-01, Volume: 179Design, synthesis and biological evaluation of 2-hydrazinyladenosine derivatives as A
AID33508Binding affinity for Adenosine A3A receptor2002Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20
Structure-affinity relationships of the affinity of 2-pyrazolyl adenosine analogues for the adenosine A2A receptor.
AID1138014Agonist activity at human recombinant adenosine receptor A2b by cAMP assay2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Adenosine A2A receptor as a drug discovery target.
AID1138018Binding affinity to human recombinant adenosine A3 receptor2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Adenosine A2A receptor as a drug discovery target.
AID1345685Human A1 receptor (Adenosine receptors)2006Nature reviews. Drug discovery, Mar, Volume: 5, Issue:3
Adenosine receptors as therapeutic targets.
AID1345618Human A2A receptor (Adenosine receptors)2006Nature reviews. Drug discovery, Mar, Volume: 5, Issue:3
Adenosine receptors as therapeutic targets.
AID1345721Human A2B receptor (Adenosine receptors)2006Nature reviews. Drug discovery, Mar, Volume: 5, Issue:3
Adenosine receptors as therapeutic targets.
AID1345822Human A3 receptor (Adenosine receptors)2006Nature reviews. Drug discovery, Mar, Volume: 5, Issue:3
Adenosine receptors as therapeutic targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (301)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's30 (9.97)29.6817
2010's209 (69.44)24.3611
2020's62 (20.60)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 60.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index60.19 (24.57)
Research Supply Index5.93 (2.92)
Research Growth Index5.39 (4.65)
Search Engine Demand Index99.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (60.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials53 (16.51%)5.53%
Reviews31 (9.66%)6.00%
Case Studies32 (9.97%)4.05%
Observational9 (2.80%)0.25%
Other196 (61.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (67)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
MyocardiAl CT Perfusion and Coronary Flow: a CompreHensive Cardiac CT Myocardial Perfusion Imaging (MPI)/Fractional Flow Reserve (FFR) and PET-CT MPI Evaluation (The MATCH Investigation) [NCT04316676]30 participants (Anticipated)Interventional2021-06-16Recruiting
An Open-label, Single-dose, Safety and Pharmacokinetic Study of Regadenoson in Pediatric Patients [NCT04604782]Phase 1/Phase 254 participants (Anticipated)Interventional2021-05-20Recruiting
Contrast- Enhanced Whole-Heart Coronary Magnetic Resonance Angiography (MRA) at 3.0T [NCT02092428]Phase 1333 participants (Actual)Interventional2011-04-30Completed
The ESPRIT Study: Estrogen Suppression and Perfusion Reserve With Aromatase-Inhibitor Treatment in Premenopausal Women With Breast Cancer [NCT03505736]25 participants (Actual)Observational2018-06-21Completed
Quantification of Myocardial Blood Flow by Positron Emission Tomography and N-13 Ammonia During Regadenoson vs Adenosine Stress [NCT01370265]12 participants (Actual)Interventional2011-02-28Completed
Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension [NCT02220634]10 participants (Actual)Interventional2014-08-31Terminated(stopped due to PI left National Jewish Health)
Regadenoson Stress Real-Time Myocardial Perfusion Echocardiography for Detection of Coronary Artery Disease Feasibility and Accuracy of Two Different Ultrasound Contrast Agents [NCT01489176]Phase 350 participants (Actual)Interventional2012-07-31Completed
A Phase 4, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD). [NCT00862641]Phase 41,009 participants (Actual)Interventional2009-04-30Completed
Arm Exercise Versus Pharmacologic Stress Testing for Clinical Outcome Prediction [NCT03449888]133 participants (Actual)Observational2018-07-01Terminated(stopped due to Terminated by the local IRB)
Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging [NCT00857792]120 participants (Actual)Interventional2009-03-31Completed
Comparison of Dobutamine and Regadenoson Stress CMR [NCT00763035]Early Phase 114 participants (Actual)Interventional2009-01-31Terminated(stopped due to Potential participants with COPD/asthma unwilling to participate.)
Comparison of New MRI Methods for Quantitative Assessment of Myocardial Perfusion With Quantitative PET Perfusion Imaging [NCT02608944]0 participants (Actual)Interventional2012-09-30Withdrawn(stopped due to MRI perfusion techniques development took longer than expected.)
A Phase 3b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Caffeine Intake on Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) in Subjects Administered Regadenoson [NCT00826280]Phase 3347 participants (Actual)Interventional2009-03-24Completed
Assessment and Prognostic Significance of Global Myocardial Perfusion Reserve Using Coronary Sinus Flow Measurements During Regadenoson Stress Cardiac Magnetic Resonance [NCT02697877]183 participants (Actual)Observational2016-02-29Completed
Feasibility of Detecting Myocardial Ischemia by First-pass Contrast MRI Using Regadenoson [NCT00881218]Early Phase 150 participants (Actual)Interventional2009-06-30Completed
Regadenoson Real Time Perfusion Imaging Trial [NCT00837369]100 participants (Actual)Interventional2009-05-31Completed
A Phase 4, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment [NCT00863707]Phase 4511 participants (Actual)Interventional2009-04-30Completed
Lexiscan(TM) Rb-82 Myocardial Perfusion Positron Emission Computed Tomography: A Comparison With Dipyridamole [NCT00808314]Phase 432 participants (Anticipated)Interventional2008-12-31Active, not recruiting
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D) [NCT01019486]Phase 426 participants (Actual)Interventional2009-11-30Completed
An Open-Label, Parallel-Group, Exploratory Study to Evaluate the Efficacy and Safety of 400 ug Regadenoson Bolus for Pharmacological Stress Echocardiography [NCT00907764]Phase 222 participants (Actual)Interventional2009-04-30Terminated(stopped due to Slow enrollment)
Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes: Modulation by Glucagon-Like-Peptide-1 [NCT01021865]33 participants (Actual)Observational2010-02-28Completed
A Phase 1, Randomized, Double-blind, Dose Escalation, Parallel Group, Placebo-controlled, Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects [NCT01918995]Phase 136 participants (Actual)Interventional2013-05-31Completed
Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas [NCT03971734]Phase 17 participants (Actual)Interventional2019-12-06Terminated(stopped due to Terminated [NCI decided to terminate ABTC Consortium due to NCI moving in different direction for Brain Cancer])
Use of Regadenoson for a Stress Echocardiogram Protocol Using Speckle Tracking Imaging [NCT02130453]Phase 4300 participants (Anticipated)Interventional2014-08-28Active, not recruiting
New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF) [NCT04600115]Early Phase 1100 participants (Anticipated)Interventional2017-03-03Recruiting
Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease [NCT01085201]Phase 139 participants (Actual)Interventional2010-04-30Completed
Integrated Dual Exercise and Lexiscan PET: IDEAL PET [NCT01109992]Phase 443 participants (Actual)Interventional2011-02-28Completed
A Phase 2, Open-Label, Randomized, Cross-Over Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging by Multidetector Computed Tomography (MDCT) and Single Photon Emission Computed Tomography (SPECT) [NCT01334918]Phase 2124 participants (Actual)Interventional2011-04-26Completed
Comparison of Anti-gravity Treadmill Exercise and Regadenoson Tc-99m Tetrofosmin Single-photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging [NCT02628002]49 participants (Actual)Interventional2015-12-31Completed
Myocardial Perfusion Assessment With Multidetector Computed Tomography [NCT00846079]Phase 3100 participants (Anticipated)Interventional2009-02-28Active, not recruiting
Effects of Body Mass Index on the Hyperemic Response to Regadenoson [NCT00859833]30 participants (Actual)Interventional2009-02-28Completed
Diagnostic Value of a Rapid Protocol Regadenoson Stress Cardiovascular Magnetic Resonance Scan for Detection of Coronary Artery Disease [NCT01446094]Phase 450 participants (Anticipated)Interventional2011-08-31Recruiting
Detection of Coronary Artery Disease in Patients With Atrial Fibrillation Using Regadenoson Stress MRI [NCT01710254]Phase 230 participants (Actual)Interventional2013-01-31Completed
Stress Testing and Cardiac Magnetic Resonance [NCT00871260]Phase 420 participants (Actual)Interventional2009-04-30Completed
A Phase III, Randomized, Double-Blind Study of Intravenous CVT-3146 Versus Adenoscan® in Patients Undergoing Stress Myocardial Perfusion Imaging [NCT00208299]Phase 31,231 participants (Actual)Interventional2003-10-31Completed
Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI [NCT01655043]Phase 220 participants (Actual)Interventional2012-09-30Completed
Effect of Adenosine 2A Receptor Agonist Regadenoson on Microvascular Blood Flow in Sickle Cell Anemia [NCT01566890]200 participants (Anticipated)Interventional2012-07-31Active, not recruiting
A Phase III, Randomized, Double-Blind Study of Intravenous CVT-3146 Versus Adenoscan® in Patients Undergoing Stress Myocardial Perfusion Imaging [NCT00208312]Phase 3787 participants (Actual)Interventional2004-04-30Completed
Artifact-Free High-resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies [NCT01949844]44 participants (Actual)Interventional2014-05-16Completed
Utilization of Lexiscan (Regadenoson)in the Cardiac Catheterization Lab to Achieve Maximal Hyperemia for Coronary Physiologic Assessment With Fractional Flow Reserve [NCT01161121]Phase 146 participants (Actual)Interventional2010-07-31Completed
A Randomized, Double-blind, Placebo-controlled Parallel Arm Dose Titration Study to Assess the Effects of SAR407899 in Patients With Microvascular Angina (MVA) and/or Persistent Stable Angina Despite Angiographically Successful Percutaneous Coronary Inter [NCT03236311]Phase 210 participants (Actual)Interventional2017-10-12Terminated(stopped due to (Recruitment was early terminated due to slow recruitment. Not linked to any safety concern.))
A Phase 3b, Open-Label, Parallel Group, Randomized, Multicenter Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Co [NCT01618669]Phase 31,147 participants (Actual)Interventional2012-06-30Completed
Comparison of Regadenoson (Rapiscan) and Central Intravenous Adenosine for Measurement of Fractional Flow Reserve [NCT01809743]Phase 3100 participants (Actual)Interventional2013-01-31Completed
Regional and Global Left Ventricular Mechanical Dyssynchrony in the Diagnosis of Obstructive Coronary Artery Disease on Rest and Regadenoson Stress Rubidium Myocardial Perfusion PET [NCT01840696]Phase 20 participants (Actual)Interventional2013-10-31Withdrawn(stopped due to PI leaving facility)
Whole-Heart Myocardial Blood Flow Quantification Using Magnetic Resonance Imaging [NCT03064295]160 participants (Anticipated)Observational2018-03-01Recruiting
Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation [NCT01919450]Phase 480 participants (Actual)Interventional2013-07-31Completed
Evaluation of the Normal Distribution of Rubidium-82(Rb-82), Nitrogen-13 (N-13)Ammonia, and Fluorine-18 Fluorodeoxyglucose (F-18FDG) in Normal Volunteers [NCT01433705]Phase 170 participants (Actual)Interventional2011-11-30Completed
Maximal Bruce Protocol With the Use of Regadenoson For Myocardial Perfusion Stress Testing [NCT01026012]40 participants (Actual)Interventional2009-12-31Completed
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia [NCT01788631]Phase 2100 participants (Actual)Interventional2013-07-31Completed
Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF [NCT02589977]Phase 455 participants (Actual)Interventional2015-11-30Completed
Stress Cardiac MRI Using Regadenoson for Evaluation of Nonspecific Allograft Dysfunction [NCT02597543]Phase 414 participants (Actual)Interventional2015-11-30Completed
Comprehensive Evaluation of Patients With Chest Pain Using Cardiac Computed Tomography: Value of Adding Regadenoson Stress Perfusion Imaging to Noninvasive Coronary Angiography [NCT01969916]150 participants (Actual)Interventional2014-06-30Completed
Use of Lexiscan for Myocardial Stress Perfusion Computed Tomography With a 3rd Generation Dual Source CT System [NCT03103061]Phase 224 participants (Actual)Interventional2016-02-09Completed
Clinical Trial on the Safety and Efficacy of Regadenoson for Moderate to Severe COVID-19 Adult Patients [NCT04606069]Phase 1/Phase 25 participants (Actual)Interventional2021-05-06Completed
A Randomized, Blinded, Multi-site, Pilot Study to Evaluate Adenosine 2A Receptor Agonist (REGADENOSON) in the Rehabilitation of Marginal Donor Lungs. [NCT04521569]Early Phase 146 participants (Anticipated)Interventional2020-06-22Recruiting
Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve [NCT03249272]Phase 431 participants (Actual)Interventional2017-09-05Terminated(stopped due to Sponsor withdrew funding)
An Evaluation of the Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET (Stress-Rest) Myocardial Perfusion Imaging (MYPERS) [NCT05583721]Phase 240 participants (Anticipated)Interventional2023-10-10Recruiting
Efficacy of Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve Measurements [NCT01482169]48 participants (Actual)Interventional2012-03-31Completed
The Effect of A2A Adrenoceptor Stimulation on the Diameter of Retinal Arterioles During Hypoxia in Vivo [NCT03090087]Phase 220 participants (Anticipated)Interventional2017-03-22Recruiting
Defining Mechanisms for Cardiac Allograft Dysfunction to Improve Allograft Longevity and Survival in Heart-Transplant Patients [NCT03102125]Phase 4376 participants (Anticipated)Interventional2019-10-01Recruiting
The Ex-Lex Trial: A Randomized Trial Combining Regadenoson With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging [NCT01021618]140 participants (Actual)Interventional2010-01-31Completed
A Phase 1 Open Label Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation [NCT03072589]Phase 121 participants (Anticipated)Interventional2017-11-30Recruiting
Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson [NCT01779869]Phase 416 participants (Actual)Interventional2013-01-31Completed
Quantitative Rest/Stress Cardiac Perfusion Digital PET/CT: Comparison Between Noninvasive Imaging and Invasive Coronary Angiography. [NCT03170817]15 participants (Actual)Observational2017-03-29Completed
Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging [NCT02115308]Phase 440 participants (Actual)Interventional2014-09-03Completed
Heart Rate Response to Regadenoson and Sudden Cardiac Death [NCT01842035]90 participants (Actual)Interventional2013-02-28Completed
Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration [NCT02389738]Early Phase 16 participants (Actual)Interventional2015-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00763035 (7) [back to overview]Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare Tech Questionnaire
NCT00763035 (7) [back to overview]Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare Nurse Questionnaire (Episodes of Arrhythmias, Bradycardia, Hypertension, and Wheezing)
NCT00763035 (7) [back to overview]Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare Tech Questionnaire (Episodes of Wheezing)
NCT00763035 (7) [back to overview]Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare MD Questionnaire
NCT00763035 (7) [back to overview]Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare Nurse Questionnaire
NCT00763035 (7) [back to overview]Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare MD Questionnaire (Episodes of Arrhythmias, Bradycardia, and Wheezing)
NCT00763035 (7) [back to overview]Duration of Procedures
NCT00826280 (7) [back to overview]Change in Number of Reversible Defects
NCT00826280 (7) [back to overview]Change in Number of Reversible Defects Assessed by Computerized Quantitation
NCT00826280 (7) [back to overview]Change From Baseline in Systolic Blood Pressure
NCT00826280 (7) [back to overview]Change From Baseline in Diastolic Blood Pressure
NCT00826280 (7) [back to overview]Change From Baseline in Heart Rate
NCT00826280 (7) [back to overview]Change in Summed Difference Score (SDS) Across All 17 Segments
NCT00826280 (7) [back to overview]Change in Summed Difference Score Across All 17 Segments Assessed by Computerized Quantitation
NCT00857792 (1) [back to overview]Ability to Detect Stress-induced Myocardial Perfusion Abnormalities by Analysis of MDCT Images Confirmed by Coronary Angiography and/or SPECT.
NCT00859833 (1) [back to overview]Myocardial Perfusion Reserve Measured by Quantitative Perfusion MRI (Ratio of Myocardial Blood Flow During Stress Over Myocardial Blood Flow at Rest)
NCT00862641 (9) [back to overview]Change From Baseline to the 2 Hour Post-dose Assessment for FEV1 Absolute Values
NCT00862641 (9) [back to overview]Change From Baseline to the 2 Hour Post-dose Assessment for FEV1 Percent Predicted
NCT00862641 (9) [back to overview]Change From Baseline to the 2 Hour Post-dose Assessment for FEV1/ FVC Ratio
NCT00862641 (9) [back to overview]Change From Baseline to the 2 Hour Post-dose Assessment for Forced Vital Capacity (FVC)
NCT00862641 (9) [back to overview]Change From Baseline to the 2 Hour Post-dose Assessment for Oxygen Saturation Measured by Pulse Oximetry
NCT00862641 (9) [back to overview]Use of Short-acting Bronchodilators for Treatment of Symptoms After Study Drug Administration
NCT00862641 (9) [back to overview]Percentage of Selected Respiratory Adverse Events
NCT00862641 (9) [back to overview]Percentage of Subjects Who Had a >15% Decrease in Forced Expiratory Volume in 1 Second (FEV1) at the 2-hour Postbaseline Assessment
NCT00862641 (9) [back to overview]Use of Short-acting Bronchodilators for Treatment of Symptoms After Study Drug Administration
NCT00863707 (1) [back to overview]Number of Subject With Serious Treatment Emergent Adverse Events (TEAE)
NCT00871260 (1) [back to overview]Major Adverse Cardiovascular Events
NCT01019486 (3) [back to overview]Coronary Blood Flow Assessment With Regadenoson Stress by Cardiac MRI Between Non-diabetic and Type 1 Diabetic Subjects.
NCT01019486 (3) [back to overview]Measured Coronary Blood Flow is Directly Correlated With Coronary Flow Reserve Measured Invasively in the Cardiac Catheterization Laboratory After Regadenoson Pharmacologic Stress.
NCT01019486 (3) [back to overview]Myocardial Perfusion Index
NCT01021618 (2) [back to overview]Myocardial Perfusion Image Quality
NCT01021618 (2) [back to overview]"Number of Participants With Major Adverse Events or Side Effects Graded Severe on Symptom Questionnaire"
NCT01026012 (1) [back to overview]Number of Participants With Side Effects, Including Dyspnea, Headache, Dizziness, Chest Pain, Nausea, Abdominal Discomfort, Dysgeusia, Flushing, and Symptomatic Hypotension and Others.
NCT01085201 (3) [back to overview]Dose Limiting Toxicities as a Measure of Whether Infusional Lexiscan is Safe in Individuals With SCD.
NCT01085201 (3) [back to overview]Pain Levels During a Vaso-occlusive Event in Children and Adults With SCD.
NCT01085201 (3) [back to overview]Percentage of Activated iNKT Cells and/or Activation Markers on iNKT Cells in Individuals With SCD.
NCT01109992 (4) [back to overview]Changes in Left Ventricular Function With Dual Exercise and Regadenoson PET
NCT01109992 (4) [back to overview]Image Quality: Heart to Liver Ratio of Counts
NCT01109992 (4) [back to overview]Peak Stress Myocardial Blood Flow
NCT01109992 (4) [back to overview]Safety and Tolerability of Combined Exercise and Regadenoson Stress
NCT01161121 (3) [back to overview]Side Effects of Medication Administration
NCT01161121 (3) [back to overview]Heart Rate Changes With Drug
NCT01161121 (3) [back to overview]Difference in FFR Between IV Adenosine and IV Regadenoson
NCT01334918 (7) [back to overview]Number of Participants With Reversible Defects
NCT01334918 (7) [back to overview]Percentage of Participants With Two or More Ischemic Segments on SPECT, But Less on CT
NCT01334918 (7) [back to overview]Number of Participants With Fixed Defects
NCT01334918 (7) [back to overview]Number of Participants With Reversible Defects in the Left Anterior Descending Coronary Artery (LAD)
NCT01334918 (7) [back to overview]Number of Participants With Reversible Defects in the Left Circumflex Coronary Artery (LCX)
NCT01334918 (7) [back to overview]Number of Participants With Reversible Defects in the Right Coronary Artery (RCA)
NCT01334918 (7) [back to overview]Overall Image Quality of Scans by Modality and Reviewer
NCT01370265 (7) [back to overview]Global Hyperemic Myocardial Blood Flow (MBF)
NCT01370265 (7) [back to overview]Heart Rate (Beats Per Minute (BPM))
NCT01370265 (7) [back to overview]Hyperemic Blood Pressure (mmHg)
NCT01370265 (7) [back to overview]Hyperemic Segmental MBF
NCT01370265 (7) [back to overview]Resting Global MBF and Resting Segmental MBF
NCT01370265 (7) [back to overview]Segmental CFR
NCT01370265 (7) [back to overview]Global Cardiac Flow Rate
NCT01482169 (2) [back to overview]Comparing Measurement of Fractional Flow Reserve (FFR)
NCT01482169 (2) [back to overview]Duration to Baseline Hyperemia After Aminophylline Injection
NCT01489176 (1) [back to overview]Number of Participants With Coronary Stenosis
NCT01618669 (12) [back to overview]Overall Assessment of Image Quality
NCT01618669 (12) [back to overview]Target to Background Radiotracer Uptake Ratios From the First and Second Stress Scans
NCT01618669 (12) [back to overview]Proportion of Participants With Agreement in the Assessment of Absence or Presence of Ischemia Between First and Second Stress Scans
NCT01618669 (12) [back to overview]Proportion of Participants With Agreement in the Assessment of Reversible Defects in 3 Categories of Ischemia Between First and Second Stress Scans
NCT01618669 (12) [back to overview]Proportion of Participants With Agreement in the Summed Stress Score (SSS) Between First and Second Stress Scans
NCT01618669 (12) [back to overview]Proportion of Participants With Majority Reader Self-agreement in Ischemia Assessment Between First and Second Stress Scans
NCT01618669 (12) [back to overview]Number of Participants With Adverse Events Within 24 Hours After Administration of Regadenoson
NCT01618669 (12) [back to overview]Participants With Less, the Same, or More Reversible Perfusion Defects Shown by the First Stress Scan When Compared to the Second Stress Scan
NCT01618669 (12) [back to overview]Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
NCT01618669 (12) [back to overview]Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
NCT01618669 (12) [back to overview]Percentage of Scans With Subdiaphragmatic Interference
NCT01618669 (12) [back to overview]Proportion of Participants With Agreement in the Summed Difference Score (SDS) Between First and Second Stress Scans
NCT01655043 (1) [back to overview]Quantification of Myocardial Blood Volume
NCT01710254 (3) [back to overview]Sensitivity of Regadenoson Stress-MRI for Detection of Coronary Artery Disease (CAD)
NCT01710254 (3) [back to overview]Accuracy of Regadenoson Stress-MRI for Detection of Coronary Artery Disease (CAD)
NCT01710254 (3) [back to overview]Specificity of Regadenoson Stress-MRI for Detection of Coronary Artery Disease (CAD)
NCT01779869 (1) [back to overview]Diagnostic Accuracy of Cardiac PET/MRI Examination
NCT01788631 (7) [back to overview]Level of Inflammatory Markers (IL-4)
NCT01788631 (7) [back to overview]Number of Participants With a Reduction in Invariant Natural-Killer T-Cell (iNKT Cell) Activation by 70% or More
NCT01788631 (7) [back to overview]Number of Participants With an Improvement in Respiratory Symptoms
NCT01788631 (7) [back to overview]Opioid Use
NCT01788631 (7) [back to overview]Length of Hospital Stay
NCT01788631 (7) [back to overview]Level of Inflammatory Markers (A2A)
NCT01788631 (7) [back to overview]Level of Inflammatory Markers (IFN-gamma)
NCT01842035 (6) [back to overview]All-cause Death
NCT01842035 (6) [back to overview]All-cause Death or First Appropriate ICD Therapy
NCT01842035 (6) [back to overview]First Appropriate ICD Therapy
NCT01842035 (6) [back to overview]Inappropriate ICD Therapy
NCT01842035 (6) [back to overview]Sudden Cardiac Death
NCT01842035 (6) [back to overview]Sudden Cardiac Death or Appropriate ICD Therapy
NCT01919450 (4) [back to overview]Measure Quantitated Myocardial Perfusion Reserve After a 10 Second Delay in Lexiscan (Regadenoson)
NCT01919450 (4) [back to overview]Measure Quantitated Myocardial Perfusion Reserve After a 2 Minute Delay in Lexiscan (Regadenoson)
NCT01919450 (4) [back to overview]Measure Quantitated Myocardial Perfusion Reserve After a 4 Minute Delay in Lexiscan (Regadenoson)
NCT01919450 (4) [back to overview]Measure Quantitated Myocardial Perfusion Reserve After a 1 Minute Delay in Lexiscan (Regadenoson)
NCT01949844 (1) [back to overview]Diagnostic Performance (Specificity and Sensitivity) for Detection of Myocardial Perfusion Deficits on Magnetic Resonance (MR) Images
NCT01969916 (1) [back to overview]Number of Participants With Detected Stress-induced Perfusion Abnormalities by 3D Analysis of MDCT Images
NCT02115308 (4) [back to overview]Late Gadolinium Enhancement and CIRCUMFERENTIAL Myocardial Strain
NCT02115308 (4) [back to overview]CIRCUMFERENTIAL STRAIN
NCT02115308 (4) [back to overview]Late Gadolinium Enhancement (LGE) and RADIAL Myocardial Strain
NCT02115308 (4) [back to overview]RADIAL STRAIN
NCT02389738 (1) [back to overview]Change in AUC0-18 of the Temozolomide Concentration (AUC-T) in Brain Interstitium Before and After Regadenoson Infusion
NCT02589977 (5) [back to overview]Coronary Flow Reserve
NCT02589977 (5) [back to overview]E/e' by Echo in Each Study Group.
NCT02589977 (5) [back to overview]Extracellular Volume (ECV) by CMR in Each Study Group
NCT02589977 (5) [back to overview]Oxidative Metabolism (Kmono/Rate Pressure Product) by PET in Each Study Group.
NCT02589977 (5) [back to overview]Myocardial Perfusion Reserve by CMR in Each Study Group.
NCT02597543 (6) [back to overview]Myocardial Perfusion Reserve
NCT02597543 (6) [back to overview]Re-transplantation
NCT02597543 (6) [back to overview]Hospitalization for Cardiac Related Causes
NCT02597543 (6) [back to overview]Late Gadolinium Enhancement
NCT02597543 (6) [back to overview]Mean Segmental T1 Values of the Left Ventricle
NCT02597543 (6) [back to overview]Myocardial Ischemia/Infarction
NCT03103061 (2) [back to overview]Number of Treatment-related Adverse Events
NCT03103061 (2) [back to overview]Diagnostic Accuracy Using Quantitative Objective Image Quality Assessment
NCT03236311 (1) [back to overview]Change From Baseline in Uncorrected Global Coronary Flow Reserve (CFR) at Week 4
NCT03249272 (3) [back to overview]CMR Measurement of Global Perfusion Reserve Ratio
NCT03249272 (3) [back to overview]Prevalence of Microvascular Dysfunction (MVD) by a CMR Measurement of Whole-heart (Global) Perfusion Reserve Ratio in Patients With Hypertrophic Cardiomyopathy, Non-ischemic Cardiomyopathy, and Controls.
NCT03249272 (3) [back to overview]The Association Between Global Perfusion Reserve (GPR) Ratio and Regional Myocardial Scarring.

Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare Tech Questionnaire

To compare the ease of administration of regadenoson verses intravenous dobutamine during pharmacological stress testing in individuals with moderate to severe chronic obstructive pulmonary disease (COPD) or asthma. Patient Comfort - Scale from 1(very comfortable) to 4(very uncomfortable), low score represent better outcome. Interruptions during the procedure - Scale from 1(1-2) to 4(>6), low score represent better outcome. Level of monitoring - Scale from 1(most easy among all MRI tests) to 4(most difficult), low score represent better outcome. Level of anxiety while during the procedure - Scale from 1(less than any other MRI stress test) to 4(the most), low score represent better outcome. Overall rating of the procedure - Scale from 1(very difficult) to 4(very easy), higher scores represent better outcome. (NCT00763035)
Timeframe: 1 day

,
Interventionunits on a scale (Mean)
Patient ComfortInterruptions during the procedureLevel of monitoringLevel of anxiety while during the procedureOverall rating of the procedure
Dobutamine1.20.62.71.83.5
Regadenoson1.50.11.11.34.3

[back to top]

Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare Nurse Questionnaire (Episodes of Arrhythmias, Bradycardia, Hypertension, and Wheezing)

To compare the ease of administration of regadenoson verses intravenous dobutamine during pharmacological stress testing in individuals with moderate to severe chronic obstructive pulmonary disease (COPD) or asthma. Episodes of (SBP>140), low number represent better outcome. Episodes of arrhythmias (including PVCs) and bradycardia (HR<60), low number represent better outcome. Episodes of wheezing and SPO2<94%, low number represent better outcome. (NCT00763035)
Timeframe: 1 day

,
Interventionnumber of episodes (Mean)
Episodes of hypertensionEpisodes of arrhythmias and bradycardiaEpisodes of wheezing and SPO2<94%
Dobutamine1.6.80.0
Regadenoson2.80.0

[back to top]

Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare Tech Questionnaire (Episodes of Wheezing)

To compare the ease of administration of regadenoson verses intravenous dobutamine during pharmacological stress testing in individuals with moderate to severe chronic obstructive pulmonary disease (COPD) or asthma. Low scores represent better outcome. (NCT00763035)
Timeframe: 1 day

Interventionnumber of episodes (Mean)
Dobutamine.2
Regadenoson0.0

[back to top]

Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare MD Questionnaire

The Compare MD tool have the following scales: Ease of Administration - Scale from 1(most easy among all MRI stress tests) to 5(most difficult), low score represent better outcome. Patient Comfort - Scale from 1(very comfortable) to 4(very uncomfortable), low score represent better outcome. Interruptions during the procedure - Scale from 1(1-2) to 4(>6), low score represent better outcome. Side effects - Scale from 1(fewer than any other MRI stress test) to 4(the most), low score represent better outcome. Level of anxiety while during the procedure - Scale from 1(less than any other MRI stress test) to 4(the most), low score represent better outcome. Overall rating of the procedure (1 very Difficult to 5 very easy), higher scores represent better outcomes. (NCT00763035)
Timeframe: 1 day

,
Interventionunits on a scale (Mean)
Ease of administrationPatient ComfortInterruptions during the procedureSide effectsLevel of anxiety while during the procedureOverall rating of the procedure
Dobutamine2.91.80.52.32.44.3
Regadenoson1.91.50.11.61.54.1

[back to top]

Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare Nurse Questionnaire

To compare the ease of administration of regadenoson verses intravenous dobutamine during pharmacological stress testing in individuals with moderate to severe chronic obstructive pulmonary disease (COPD) or asthma. Ease of Administration - Scale from 1(most easy among all MRI stress tests) to 5(most difficult), low score represent better outcome. Patient Comfort - Scale from 1(very comfortable) to 4(very uncomfortable), low score represent better outcome. Interruptions during the procedure - Scale from 1(1-2) to 4(>6), low score represent better outcome. Side effects - Scale from 1(fewer than any other MRI stress test) to 4(the most), low score represent better outcome. (NCT00763035)
Timeframe: 1 day

,
Interventionunits on a scale (Mean)
Ease of administrationPatient ComfortInterruptions during the procedureSide effects
Dobutamine3.42.30.62.0
Regadenoson1.51.50.11.3

[back to top]

Ease of Administration of Regadenoson Versus Intravenous Dobutamine Using Compare MD Questionnaire (Episodes of Arrhythmias, Bradycardia, and Wheezing)

Ease of Administration of regadenoson versus intravenous dobutamine using Compare MD Questionnaire. Episodes of arrhythmias (including PVCs) and bradycardia (HR<60), low score represent better outcome. Number of Episodes of wheezing and SPO2<94%, low numbers represent better outcome. (NCT00763035)
Timeframe: 1 day

,
Interventionnumber of episodes (Mean)
Episodes of arrhythmias and bradycardiaEpisodes of wheezing and SPO2<94%
Dobutamine0.60.0
Regadenoson0.10.0

[back to top]

Duration of Procedures

To compare the time involved during pharmacologic stress testing using regadenoson versus intravenous dobutamine in individuals with moderate to severe chronic obstructive pulmonary disease (COPD)or asthma. (NCT00763035)
Timeframe: 1 day

InterventionMinutes (Mean)
Dobutamine48
Regadenoson55

[back to top]

Change in Number of Reversible Defects

"Each segment of the 17-Segment Model was assessed for radiotracer uptake on a scale of 0 (normal uptake) to 4 (absent uptake). Segments were counted as having a reversible defect if the stress score was greater than the rest score and the stress score was ≥ 2.~Change was calculated as the number of reversible defects using regadenoson with caffeine/placebo (Day 5) minus the number of reversible defects using regadenoson alone (Day 3)." (NCT00826280)
Timeframe: Day 3 and Day 5

,,
InterventionReversible Defects (Mean)
Baseline Stress Scan (Day 3)Double-Blind Stress Scan (Day 5)DoubleBlind - Baseline (Day 5 - Day 3)
Caffeine 200 mg Plus Regadenoson1.010.40-0.61
Caffeine 400 mg Plus Regadenoson1.000.38-0.62
Placebo Plus Regadenoson0.670.800.12

[back to top]

Change in Number of Reversible Defects Assessed by Computerized Quantitation

"Each segment of the 17-Segment Model was assessed for radiotracer uptake on a scale of 0 (normal uptake) to 4 (absent uptake). Segments were counted as having a reversible defect if the stress score was greater than the rest score and the stress score was ≥ 2.~Change was calculated as the number of reversible defects using regadenoson with caffeine/placebo (Day 5) minus the number of reversible defects using regadenoson alone (Day 3)." (NCT00826280)
Timeframe: Day 3 and Day 5

,,
InterventionReversible Defects (Mean)
Baseline Stress Scan (Day 3) [N=64; 69; 70]Double-Blind Stress Scan (Day 5) [N=66; 70; 71]DoubleBlind - Baseline (Day 5-Day 3)[N=64; 69; 70]
Caffeine 200 mg Plus Regadenoson2.001.46-0.59
Caffeine 400 mg Plus Regadenoson2.191.42-0.81
Placebo Plus Regadenoson1.471.740.31

[back to top]

Change From Baseline in Systolic Blood Pressure

"Baseline is the last non-missing measurement on or before first dose of regadenoson.~Change is calculated as the time point minus baseline." (NCT00826280)
Timeframe: Baseline, Day 5 (-3 min), Day 5 (+3 min), Day 5 (+15 min)

,,
InterventionmmHg (Median)
Baseline [N=113; 116; 116]Change at Day 5 (- 3 min) [N=67;70;71]Change at Day 5 (+3 min) [N=67; 70; 72]Change at Day 5 (+15 min) [N=66; 72; 72]
Caffeine 200 mg Plus Regadenoson131.012.08.08.0
Caffeine 400 mg Plus Regadenoson135.011.07.55.0
Placebo Plus Regadenoson135.00.00.0-2.0

[back to top]

Change From Baseline in Diastolic Blood Pressure

"Baseline is the last non-missing measurement on or before first dose of regadenoson.~Change is calculated as the time point minus baseline." (NCT00826280)
Timeframe: Baseline, Day 5 (-3 min), Day 5 (+3 min), Day 5 (+15 min)

,,
InterventionmmHg (Median)
Baseline [N= 113; 116;116]Change at Day 5 (- 3 min) [N=67; 70; 71]Change at Day 5 (+ 3 min) [N=67; 70; 72]Change at Day 5 (+15 min) [N=66; 72; 72]
Caffeine 200 mg Plus Regadenoson74.04.04.03.0
Caffeine 400 mg Plus Regadenoson73.06.03.04.0
Placebo Plus Regadenoson78.00.0-1.0-2.0

[back to top]

Change From Baseline in Heart Rate

"Baseline is the last non-missing measurement on or before first dose of regadenoson~Change is calculated as the time point minus baseline." (NCT00826280)
Timeframe: Baseline, Day 5 (-3 min), Day 5 (+3 min), Day 5 (+15 min)

,,
InterventionBeats per minute (Median)
Baseline [N=113; 116; 116]Change at Day 5 (- 3 min) [N=67; 70; 71]Change at Day 5 (+3 min) [N=67; 70; 72]Change at Day 5 (+15 min) [N=66; 72; 72]
Caffeine 200 mg Plus Regadenoson62.0-1.05.01.0
Caffeine 400 mg Plus Regadenoson64.0-2.00.0-1.0
Placebo Plus Regadenoson66.0-2.09.04.0

[back to top]

Change in Summed Difference Score (SDS) Across All 17 Segments

"The Summed Difference Score was calculated as the difference in the Summed Stress Score across the 17 segments (scan run under stress condition) minus the Summed Rest Score across the 17 segments (scan run under rest conditions).~Change in SDS was calculated as the SDS for regadenoson with caffeine/placebo stress scan (Day 5) minus the SDS for regadenoson only stress scan (Day 3).~The full range of the SDS is -68 to 68, where 0 represents no change between Summed Stress Score and Summed Rest Score. A higher positive score indicates more severe coronary artery disease (CAD)." (NCT00826280)
Timeframe: Day 3 and Day 5

,,
InterventionSum Difference Score (Mean)
Baseline Stress Scan (Day 3)Double-Blind Stress Scan (Day 5)DoubleBlind - Baseline (Day 5 - Day 3)
Caffeine 200 mg Plus Regadenoson2.451.42-1.03
Caffeine 400 mg Plus Regadenoson2.531.27-1.25
Placebo Plus Regadenoson2.242.360.11

[back to top]

Change in Summed Difference Score Across All 17 Segments Assessed by Computerized Quantitation

"The Summed Difference Score was calculated as the difference in the Summed Stress Score across the 17 segments (scan run under stress condition) minus the Summed Rest Score across the 17 segments (scan run under rest conditions).~Change in SDS was calculated as the SDS for regadenoson with caffeine/placebo stress scan (Day 5) minus the SDS for regadenoson only stress scan (Day 3).~The full range of the SDS is -68 to 68, where 0 represents no change between Summed Stress Score and Summed Rest Score. A higher positive score indicates more severe coronary artery disease (CAD)." (NCT00826280)
Timeframe: Day 3 and Day 5

,,
InterventionSummed Difference Score (Mean)
Baseline Stress Scan (Day 3) [N=64; 69; 70]Double-Blind Stress Scan (Day 5) [N=66; 70; 71]DoubleBlind - Baseline (Day 5-Day 3)[N=64; 69; 70]
Caffeine 200 mg Plus Regadenoson4.463.10-1.45
Caffeine 400 mg Plus Regadenoson4.292.46-1.84
Placebo Plus Regadenoson3.344.411.02

[back to top]

Ability to Detect Stress-induced Myocardial Perfusion Abnormalities by Analysis of MDCT Images Confirmed by Coronary Angiography and/or SPECT.

(NCT00857792)
Timeframe: 3 months

Intervention% accurately detected perfusion defects (Number)
Open Label78

[back to top]

Myocardial Perfusion Reserve Measured by Quantitative Perfusion MRI (Ratio of Myocardial Blood Flow During Stress Over Myocardial Blood Flow at Rest)

The ratio of myocardial blood flow during stress (with each vasodilator) divided by the myocardial flood flow at rest = myocardial perfusion reserve (MPR) (NCT00859833)
Timeframe: 2 hours

Interventionratio (Mean)
Adenosine2.25
Regadenoson2.44

[back to top]

Change From Baseline to the 2 Hour Post-dose Assessment for FEV1 Absolute Values

"FEV1 data was obtained by spirometry measurements.~Change from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement." (NCT00862641)
Timeframe: Baseline and Hour 2

,,,
InterventionLiters (Mean)
Baseline (N=176; 356; 151; 316)Hour 2 (N=174; 351; 147; 313)Change at Hour 2 (N=174; 351; 147; 313)
Placebo - Asthma2.412.37-0.05
Placebo - COPD1.701.69-0.01
Regadenoson - Asthma2.352.33-0.01
Regadenoson - COPD1.701.700.00

[back to top]

Change From Baseline to the 2 Hour Post-dose Assessment for FEV1 Percent Predicted

"FEV1 data was obtained by spirometry measurements.~Change from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement." (NCT00862641)
Timeframe: Baseline and Hour 2

,,,
InterventionPercentage of Predicted FEV1 (Mean)
Baseline (N=176; 356; 151; 316)Hour 2 (N=174; 351; 147; 313)Change at Hour 2 (N=174; 351; 147; 313)
Placebo - Asthma81.3479.91-1.56
Placebo - COPD55.6754.89-0.56
Regadenoson - Asthma80.3280.11-0.17
Regadenoson - COPD55.6955.61-0.06

[back to top]

Change From Baseline to the 2 Hour Post-dose Assessment for FEV1/ FVC Ratio

"FEV1 and FVC data was obtained by spirometry measurements.~Change from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement." (NCT00862641)
Timeframe: Baseline and Hour 2

,,,
InterventionPercentage of FEV1 / FVC (Mean)
Baseline (N=176; 356; 151; 316)Hour 2 ( N=174; 351; 147; 313)Change at Hour 2 (N=174; 351; 147; 313)
Placebo - Asthma74.8875.110.16
Placebo - COPD61.9562.260.31
Regadenoson - Asthma74.5975.090.52
Regadenoson - COPD60.0059.72-0.30

[back to top]

Change From Baseline to the 2 Hour Post-dose Assessment for Forced Vital Capacity (FVC)

"FVC data was obtained by spirometry measurements.~Change from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement." (NCT00862641)
Timeframe: Baseline and Hour 2

,,,
InterventionLiters (Mean)
Baseline (N=176; 356; 151; 316)Hour 2 (N=174; 351; 147; 313)Change at Hour 2 (N=174; 351; 147; 313)
Placebo - Asthma3.223.17-0.06
Placebo - COPD2.752.70-0.04
Regadenoson - Asthma3.163.11-0.03
Regadenoson - COPD2.832.840.00

[back to top]

Change From Baseline to the 2 Hour Post-dose Assessment for Oxygen Saturation Measured by Pulse Oximetry

Change from Baseline is calculated as the Hour 2 measurement minus the Baseline measurement. (NCT00862641)
Timeframe: Baseline and Hour 2

,,,
InterventionPercentage of Oxygen Saturation (Mean)
Baseline (N=170; 350; 143; 302)Hour 2 (N=170; 349; 143; 299)Change at Hour 2 (N=170; 349; 143; 299)
Placebo - Asthma96.395.9-0.4
Placebo - COPD94.794.2-0.4
Regadenoson - Asthma96.396.0-0.4
Regadenoson - COPD95.094.5-0.5

[back to top]

Use of Short-acting Bronchodilators for Treatment of Symptoms After Study Drug Administration

"The data represents the numbers of subjects using short acting bronchodilators at time of selected Adverse Event (AE).~Short acting bronchodilators are defined as medications coded to drugs for obstructive airway disease.~The selected respiratory symptomatic AEs included the following preferred terms: dyspnoea, dyspnoea exertional, obstructive airways disorder, tachypnoea, & wheezing." (NCT00862641)
Timeframe: Within 24 Hours of study drug administration

InterventionSubjects (Number)
Placebo - Asthma2
Regadenoson - Asthma5
Placebo - COPD2
Regadenoson - COPD5

[back to top]

Percentage of Selected Respiratory Adverse Events

"The selected respiratory Adverse Events are dyspnoea, dyspnoea exertional, obstructive airways disorder, tachypnoea and wheezing.~Subjects may have reported more than one type of Adverse Event." (NCT00862641)
Timeframe: Within 24 Hours of study drug administration

,,,
InterventionPercentage of Subjects (Number)
DyspnoeaWheezingObstructive Airways DisorderDyspnoea ExertionalTachypnoea
Placebo - Asthma1.11.1000
Placebo - COPD2.60.700.70
Regadenoson - Asthma10.73.10.300
Regadenoson - COPD18.00.9000.3

[back to top]

Percentage of Subjects Who Had a >15% Decrease in Forced Expiratory Volume in 1 Second (FEV1) at the 2-hour Postbaseline Assessment

FEV1 data was obtained by spirometry measures. (NCT00862641)
Timeframe: 2 Hours post dose

InterventionPercentage of Subjects (Number)
Placebo - Asthma2.9
Regadenoson - Asthma1.1
Placebo - COPD5.4
Regadenoson - COPD4.2

[back to top]

Use of Short-acting Bronchodilators for Treatment of Symptoms After Study Drug Administration

"The data represents the numbers of subjects using short acting bronchodilators at time of selected Adverse Event (AE).~Short acting bronchodilators are defined as medications coded to drugs for obstructive airway disease.~The selected respiratory symptomatic AEs included the following preferred terms: dyspnoea, dyspnoea exertional, obstructive airways disorder, tachypnoea, & wheezing." (NCT00862641)
Timeframe: Within 2 Hours of study drug administration

InterventionSubjects (Number)
Placebo - Asthma1
Regadenoson - Asthma1
Placebo - COPD2
Regadenoson - COPD2

[back to top]

Number of Subject With Serious Treatment Emergent Adverse Events (TEAE)

"The data represents the numbers of subjects reporting Serious TEAEs.~TEAEs were defined as Adverse Events (AEs) starting or worsening after administration of the test drug." (NCT00863707)
Timeframe: 24 hours post dose

InterventionSubjects (Number)
Placebo0
Regadenoson0

[back to top]

Major Adverse Cardiovascular Events

Major adverse cardiovascular events, such as death, myocardial infarction, unstable angina, congestive heart failure, or cerebral vascular accident. (NCT00871260)
Timeframe: 3 years

InterventionParticipants (Count of Participants)
Healthy Patients0

[back to top]

Coronary Blood Flow Assessment With Regadenoson Stress by Cardiac MRI Between Non-diabetic and Type 1 Diabetic Subjects.

Measurement of Myocardial blood flow measurements (MBF) and myocardial perfusion index obtained from 6 regions within the mid ventricular LV short axis slice. (NCT01019486)
Timeframe: 1 month

Interventionpercentage of StressMBF/ Rest MBF (Mean)
Non Diabetic Controls2.19
Type 1 Diabetes Low Risk Group1.81
Type 1 Diabetes High Risk Group1.95

[back to top]

Measured Coronary Blood Flow is Directly Correlated With Coronary Flow Reserve Measured Invasively in the Cardiac Catheterization Laboratory After Regadenoson Pharmacologic Stress.

Regional coronary blood flow reserve (CFR) in a target artery (defined on MPI study) compared to flow in a less diseased atherosclerotic vessel following vasodilator response to intravenously administered regadenoson. (NCT01019486)
Timeframe: within 6 months

InterventionCFR ratio (Mean)
Abnormal MPI Study1.5

[back to top]

Myocardial Perfusion Index

Myocardial perfusion indices radionuclide stress and rest images and were obtained from 6 regions within the mid ventricular LV short axis slice. Each was corrected for decay and standardized to a 30 mCi administered dose for each part of a two day study. (NCT01019486)
Timeframe: 1 month

Interventionpercentage of Ratio Stress/ rest counts (Mean)
Non Diabetic Controls1.09
Type 1 Diabetes Low Risk Group1.4
Type 1 Diabetes High Risk Group1.12

[back to top]

Myocardial Perfusion Image Quality

Single photon emission computed tomography myocardial perfusion acquisition and image processing was performed in accordance with American Society of Nuclear Cardiology guidelines. All images were interpreted by consensus read of three investigators blinded to stress test protocol and results. Overall perfusion and gated image quality were described as excellent (no artifacts interfering with myocardial perfusion interpretation), good, fair, or poor (artifact requiring reprocessing or repeat imaging of the patient to allow for diagnostic interpretation). (NCT01021618)
Timeframe: 0 hours

,
Interventionparticipants (Number)
ExcellentGoodFairPoor
Exercise-vasodilator Stress335570
Vasodilator-exercise Stress132550

[back to top]

"Number of Participants With Major Adverse Events or Side Effects Graded Severe on Symptom Questionnaire"

"Number of participants with any side effect (flushing, shortness of breath, headache, chest discomfort, dizziness, nausea, or abdominal pain) requiring specific treatment or graded as severe by the patient; or any death, myocardial infarction, or unplanned hospitalization. Note that 2 patients allocated to exercise-vasodilator stress did not complete symptom questionnaires and are therefore excluded from analysis." (NCT01021618)
Timeframe: 24 hours

Interventionparticipants (Number)
Vasodilator-exercise Stress11
Exercise-vasodilator Stress15

[back to top]

Number of Participants With Side Effects, Including Dyspnea, Headache, Dizziness, Chest Pain, Nausea, Abdominal Discomfort, Dysgeusia, Flushing, and Symptomatic Hypotension and Others.

Side effect will be monitored/reported by subject during stress test and 30 mins in recovery.( 1-2 hours total: for the during the subject was in the office for the test) (NCT01026012)
Timeframe: During and 30 minutes after stress test

Interventionparticipants (Number)
Combined Stress Group27

[back to top]

Dose Limiting Toxicities as a Measure of Whether Infusional Lexiscan is Safe in Individuals With SCD.

"Per protocol, Lexiscan was considered safe if well tolerated based on number of DLTs reported. Stage 1 of the study was a 3+3 dose escalation study. Three doses were tested: 0.24 mcg/kg/hr (dose level 0), 0.6 mcg/kg/hr (dose level 1), and 1.44 mcg/kg/hr (dose level 2). Dose escalation continued until 6 participants were treated at the maximum planned dose (dose level 2). We studied a total of 15 patients in Stage 1. In Stages 2 and 3, if at least 2/3 participants tolerated the dose, an additional 3 participants were studied. We studied 6 participants in each of stages 2 and 3. In stage 2b, Lexiscan was studied for a longer (48 hr) duration in 3 participants. In stage 4, Lexiscan was studied in 3 pediatric participants." (NCT01085201)
Timeframe: 30 to 54 hours plus 30-day follow-up

Interventionnumber of DLT (Number)
Stage 1 - Dose Levels 0, 1 and 21
Stage 2 - Dose Level 20
Stage 2B - Dose Level 20
Stage 3 - Dose Level 20
Stage 4 - Dose Level 20

[back to top]

Pain Levels During a Vaso-occlusive Event in Children and Adults With SCD.

Pain was measured using a standardized pain scale. The scale is a 10-cm visual analogue scale (10 cm-long line printed on white paper), where 0 is no pain and 10 is maximum pain. Participants were asked to indicate their pain level by marking on the line prior to each blood draw. (NCT01085201)
Timeframe: pre-drug to 54 hours

Interventionunits on a scale (Median)
Stage 35.8
Stage 47.8

[back to top]

Percentage of Activated iNKT Cells and/or Activation Markers on iNKT Cells in Individuals With SCD.

Percentage of activated iNKT cells after receiving a 24-hour infusion of Lexiscan was compared to pre-drug. iNKT cell activation was evaluated using antibodies targeting the p65 subunit of nuclear factor-kappa B (phospho-NF-kB p65). Measures are given as percentage of change in phospho-NF-kB p65 activation in iNKT cells compared to pre-drug after a 24-hour infusion. iNKT cell activation in Stages 1, 2b, and 4 was not analyzed (see analysis population description). (NCT01085201)
Timeframe: pre-drug to 54 hours

Interventionpercentage of change in activation (Median)
Stage 2 - Dose Level 2-3
Stage 3 - Dose Level 2-48

[back to top]

Changes in Left Ventricular Function With Dual Exercise and Regadenoson PET

"Left ventricular ejection fraction (LVEF) at stress was measured at Stress scan 1 (regadenoson) and Stress scan 2 (regadenoson or exercise + regadenoson).~This was measured on the clinical scan and on the research scan which were performed about 2 weeks apart in most subjects." (NCT01109992)
Timeframe: Week 1 (day of the clinical scan), and Week 2 (day of the research scan)

,
Interventionpercentage of LVEF (Mean)
Stress 1 ScanStress 2 Scan
Exercise + Regadenoson (Lexercise)6062
Regadenoson (Lexiscan)5859

[back to top]

Image Quality: Heart to Liver Ratio of Counts

"Sub-diaphragmatic activity: Heart to Liver Ratio was measured on the rubidium-82 and N-13 ammonia scans. Since this measure is a ratio it has no units. Mean and Standard Deviation of Ratio is reported for each group.~This was measured on the clinical scan and on the research scan which were performed about 2 weeks apart in most subjects." (NCT01109992)
Timeframe: Week 1 (day of the clinical scan), and Week 2 (day of the research scan)

,
Interventionmean ratio (Mean)
Stress Scan 1Stress Scan 2
Exercise + Regadenoson (Lexiscan)1.111.37
Regadenoson (Lexiscan)1.231.25

[back to top]

Peak Stress Myocardial Blood Flow

Myocardial Blood Flow Measured at Peak Hyperemia With Regadenoson or Immediately After Exercise + Regadenoson This was measured on the clinical scan and on the research scan which were performed about 2 weeks apart in most subjects. (NCT01109992)
Timeframe: Week 1 (day of the clinical scan), and Week 2 (day of the research scan)

,
InterventionmL/gm/min (Mean)
Stress 1 ScanStress 2 Scan
Exercise + Regadenoson (Lexiscan)2.042.34
Regadenoson (Lexiscan)1.821.85

[back to top]

Safety and Tolerability of Combined Exercise and Regadenoson Stress

"Count of subjects with ischemic ECG changes is reported~Count of subjects with systolic blood pressure decrease > 20 mm Hg is reported~Count of subjects with abnormal serum troponin T levels is reported~Radiation dose to the staff will be measured using personal dosimeters after the Lexiscan as well as the Lexercise PET study." (NCT01109992)
Timeframe: Day of the research scan during the stress test

,
InterventionParticipants (Count of Participants)
Count of ischemic ECG changesCount of subjects systolic blood pressure decreaseCount of subjects with abnormal troponin
Exercise + Regadenoson (Lexercise)300
Regadenoson (Lexiscan)030

[back to top]

Side Effects of Medication Administration

Chest pain, chest discomfort, burning, flushing, headache, nausea, or shortness of breath (NCT01161121)
Timeframe: During drug infusion and until restoration of baseline hemodynamics

,
Interventionparticipants (Number)
DyspneaChest PainAny Symptom
Adenosine141627
Regadenoson131328

[back to top]

Heart Rate Changes With Drug

Maximal heart rate documented following the administration of each agent (NCT01161121)
Timeframe: During drug infusion and until restoration of baseline hemodynamics

,
Interventionbeats per minute (Mean)
Baseline Heart RateMaximal Heart Rate
Adenosine70.881.7
Regadenosine72.490.4

[back to top]

Difference in FFR Between IV Adenosine and IV Regadenoson

FFR (as calculated by the ratio of lowest Pd/Pa at maximal hyperemia) was compared between hyperemia achieved with adenosine and with regadenoson (NCT01161121)
Timeframe: At maximal, steady-state hyperemia

Interventionratio (Pd/Pa) (Mean)
Adenosine0.84
Regadenoson0.84

[back to top]

Number of Participants With Reversible Defects

"The number of reversible defects categorized into absence or presence of ischemia (0-1 versus ≥2), as assessed by the central imaging laboratory for both SPECT and MDCT.~The 17-segment model for standardized myocardial segmentation was used for myocardial perfusion readings for SPECT and MDCT. At rest and stress, each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed:~0: normal perfusion~1: slightly reduced contrast/radiotracer uptake~2: moderately reduced contrast/radiotracer uptake~3: severely reduced contrast/radiotracer uptake~4: absent contrast/radiotracer uptake.~The median score from the 3 blinded readers for each segment was used. If the stress score was ≥ 2 and the rest score was less than the stress score, the segment was counted as having a reversible defect. A participant was classified as ischemic in the presence of 2 or more segments with reversible defects, excluding segment 17." (NCT01334918)
Timeframe: Day 1 and Day 2

,,
Interventionparticipants (Number)
SPECT: 0-1 Reversible defectsSPECT: ≥ 2 Reversible defectsSPECT: All Reversible defects
CTP: ≥ 2 Reversible Defects16925
CTP: 0 - 1 Reversible Defects84185
CTP: All Reversible Defects10010110

[back to top]

Percentage of Participants With Two or More Ischemic Segments on SPECT, But Less on CT

Using SPECT as the reference standard, the false negative percentage was calculated as the percentage of participants with two or more ischemic segments on SPECT, but less on CT. (NCT01334918)
Timeframe: Day 1 and Day 2

Interventionpercentage of participants (Number)
SPECT + MDCT10

[back to top]

Number of Participants With Fixed Defects

"Using the 17-segment scoring system, a segment scored above 1 (i.e., 2 to 4) and equal at rest and stress was counted as having a fixed defect.~At rest and stress, each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed:~0: normal perfusion~1: slightly reduced contrast/radiotracer uptake~2: moderately reduced contrast/radiotracer uptake~3: severely reduced contrast/radiotracer uptake~4: absent contrast/radiotracer uptake." (NCT01334918)
Timeframe: Day 1 and Day 2

,,
Interventionparticipants (Number)
SPECT: 0 Fixed DefectsSPECT: ≥ 1 Fixed DefectsSPECT: All Fixed Defects
CTP: ≥ 1 Fixed Defects51015
CTP: 0 Fixed Defects92395
CTP: All Fixed Defects9713110

[back to top]

Number of Participants With Reversible Defects in the Left Anterior Descending Coronary Artery (LAD)

"The number of reversible defects in the LAD categorized into absence or presence of ischemia (0-1 versus ≥2), as assessed by the central imaging laboratory for both SPECT and MDCT.~The 17-segment model for standardized myocardial segmentation was used for myocardial perfusion readings for SPECT and MDCT. At rest and stress, each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed:~0: normal perfusion~1: slightly reduced contrast/radiotracer uptake~2: moderately reduced contrast/radiotracer uptake~3: severely reduced contrast/radiotracer uptake~4: absent contrast/radiotracer uptake.~The median score from 3 blinded readers for each segment was used. If the stress score was ≥ 2 and the rest score was less than the stress score, the segment was counted as having a reversible defect. A participant was classified as ischemic in the presence of ≥ 2 segments with reversible defects, excluding segment 17." (NCT01334918)
Timeframe: Day 1 and Day 2

,,
Interventionparticipants (Number)
SPECT: 0 - 1 Reversible defectsSPECT: ≥ 2 Reversible defectsSPECT: All Reversible defects
CTP: ≥ 2 Reversible Defects11415
CTP: 0 - 1 Reversible Defects90090
CTP: All Reversible Defects1014105

[back to top]

Number of Participants With Reversible Defects in the Left Circumflex Coronary Artery (LCX)

"The number of reversible defects in the LCX categorized into absence or presence of ischemia (0-1 versus ≥2), as assessed by the central imaging laboratory for both SPECT and MDCT.~The 17-segment model for standardized myocardial segmentation was used for myocardial perfusion readings for SPECT and MDCT. At rest and stress, each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed:~0: normal perfusion~1: slightly reduced contrast/radiotracer uptake~2: moderately reduced contrast/radiotracer uptake~3: severely reduced contrast/radiotracer uptake~4: absent contrast/radiotracer uptake.~The median score from 3 blinded readers for each segment was used. If the stress score was ≥ 2 and the rest score was less than the stress score, the segment was counted as having a reversible defect. A participant was classified as ischemic in the presence of ≥ 2 segments with reversible defects, excluding segment 17." (NCT01334918)
Timeframe: Day 1 and Day 2

,,
Interventionparticipants (Number)
SPECT: 0 - 1 Reversible defectsSPECT: ≥ 2 Reversible defectsSPECT: All Reversible defects
CTP: ≥ 2 Reversible Defects9413
CTP: 0 - 1 Reversible Defects90292
CTP: All Reversible Defects996105

[back to top]

Number of Participants With Reversible Defects in the Right Coronary Artery (RCA)

"The number of reversible defects in the RCA categorized into absence or presence of ischemia (0-1 versus ≥2), as assessed by the central imaging laboratory for both SPECT and MDCT.~The 17-segment model for standardized myocardial segmentation was used for myocardial perfusion readings for SPECT and MDCT. At rest and stress, each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed:~0: normal perfusion~1: slightly reduced contrast/radiotracer uptake~2: moderately reduced contrast/radiotracer uptake~3: severely reduced contrast/radiotracer uptake~4: absent contrast/radiotracer uptake.~The median score from 3 blinded readers for each segment was used. If the stress score was ≥ 2 and the rest score was less than the stress score, the segment was counted as having a reversible defect. A participant was classified as ischemic in the presence of ≥ 2 segments with reversible defects, excluding segment 17." (NCT01334918)
Timeframe: Day 1 and Day 2

,,
Interventionparticipants (Number)
SPECT: 0 - 1 Reversible defectsSPECT: ≥ 2 Reversible defectsSPECT: All Reversible defects
CTP: ≥ 2 Reversible Defects505
CTP: 0 - 1 Reversible Defects92193
CTP: All Reversible Defects97198

[back to top]

Overall Image Quality of Scans by Modality and Reviewer

Overall image quality was assessed by three independent blinded readers for each modality (single photon emission computed tomography (SPECT) and multidetector computed tomography (MDCT)). Image quality was rated on a 4-point scale as either excellent, good, fair or poor at rest using SPECT and MDCT and under stress using regadenoson SPECT and regadenoson stress computed tomography perfusion (CTP). (NCT01334918)
Timeframe: Day 1 and Day 2

,,,,,
Interventionparticipants (Number)
Rest: ExcellentRest: GoodRest: FairRest: PoorStress: ExcellentStress: GoodStress: FairStress: Poor
MDCT: Reviewer 13056231548561
MDCT: Reviewer 240373301524629
MDCT: Reviewer 356431103736343
SPECT: Reviewer 1891641891641
SPECT: Reviewer 225533113551240
SPECT: Reviewer 3832340782750

[back to top]

Global Hyperemic Myocardial Blood Flow (MBF)

"MBF is the rate of blood supplied to the myocardium, or heart muscle. Hyperemic MBF is the rate of myocardial blood flow in the heart muscle during either regadenoson or adenosine stress. Myocardial blood flow was calculated using commercial software (PMOD Technologies, version 2.4).~The Hyperemic MBF was measured approximately 4 hours after arrival in the PET unit." (NCT01370265)
Timeframe: Day 2, approximately 4 hours after arrival in positron emission tomography (PET) unit

InterventionmL/min/gm (Mean)
Regadenoson3.1
Adenosine3.1

[back to top]

Heart Rate (Beats Per Minute (BPM))

The resting heart rate was measured approximately 35 minutes after arrival in the PET unit. The hyperemic heart rate was measured approximately 4 hours after arrival in the PET unit, depending on the randomization. (NCT01370265)
Timeframe: Day 2, approximately 35 minutes and approximately 4 hours after arrival in the PET unit

,
Interventionbpm (Mean)
Resting heart rateHyperemic heart rate
Adenosine6093
Regadenoson6298

[back to top]

Hyperemic Blood Pressure (mmHg)

Blood pressure was measured approximately 4 hours after arrival in the PET unit, depending on the randomization. (NCT01370265)
Timeframe: Day 2, approximately 4 hours after arrival in the PET unit

,
InterventionmmHg (Mean)
SystolicDiastolic
Adenosine13275
Regadenoson13072

[back to top]

Hyperemic Segmental MBF

"Regional MBFs were calculated using commercial software (PMOD Technologies, version 2.4). After the apical and basal slices of the left ventricular myocardium were chosen, the software automatically defined 4 myocardial regions of interest (segments) in the apical planes.~The hyperemic MBF was measured approximately 4 hours after arrival in the PET unit, depending on the randomization." (NCT01370265)
Timeframe: Day 2, approximately 4 hours after arrival in positron emission tomography (PET) unit

,
InterventionmL/min/gm (Mean)
Hyperemic MBF AnteriorHyperemic MBF SeptumHyperemic MBF InferiorHyperemic MBF Lateral
Adenosine2.63.23.62.9
Regadenoson2.53.13.52.9

[back to top]

Resting Global MBF and Resting Segmental MBF

"MBF is the rate of blood supplied to the myocardium, or heart muscle. Global Myocardial blood flow was calculated using commercial software (PMOD Technologies, version 2.4).~Regional MBFs were calculated using commercial software (PMOD Technologies, version 2.4). After the apical and basal slices of the left ventricular myocardium were chosen, the software automatically defined 4 myocardial regions of interest (segments) in the apical planes." (NCT01370265)
Timeframe: Day 2, approximately 35 minutes after arrival in positron emission tomography (PET) unit

Interventionml/min/gm (Mean)
Resting Global MBFResting Anterior MBFResting Septum MBFResting Inferior MBFResting Lateral MBF
Entire Study Population0.80.70.90.80.8

[back to top]

Segmental CFR

CFR was calculated using the equation: hyperemic MBF/resting MBF. (NCT01370265)
Timeframe: Day 2, approximately 4 hours after arrival in positron emission tomography (PET) unit

,
Interventionratio (Mean)
CFR AnteriorCFR SeptumCFR InferiorCFR Lateral
Adenosine3.73.64.64.0
Regadenoson3.43.54.43.9

[back to top]

Global Cardiac Flow Rate

Cardiac Flow Rate was calculated using the equation: hyperemic MBF/resting MBF. (NCT01370265)
Timeframe: Day 2, approximately 4 hours after arrival in positron emission tomography (PET) unit

Interventionratio (Mean)
Regadenoson3.8
Adenosine4.0

[back to top]

Comparing Measurement of Fractional Flow Reserve (FFR)

For the first measurement of FFR, the subject will receive Adenoscan® by IV infusion. Then the FFR measurements will be taken. When vital signs have returned to normal, after two minutes the line will be flushed with saline. The subject will then receive Regadenoson by IV infusion and repeat FFR measurements will be recorded. The subject will be administered aminophylline and the time duration it takes to return to baseline hemodynamic will be recorded. (NCT01482169)
Timeframe: DAY 1

InterventionFFR (Mean)
Adenoscan.83
Regadenoson.84

[back to top]

Duration to Baseline Hyperemia After Aminophylline Injection

In the regadenoson arm, the duration to baseline hyperemia after aminophylline Injection (NCT01482169)
Timeframe: seconds

Interventionseconds (Mean)
Duration to Baseline Hyperemia After Aminophylline Administrat112

[back to top]

Number of Participants With Coronary Stenosis

Measurements will be analyzed to identify a coronary stenosis >50% in diameter by quantitative cardiac angiography. (NCT01489176)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Regadenoson; Optison50

[back to top]

Overall Assessment of Image Quality

The image quality for each scan was rated by each independent reader as 1 = Poor, 2 = Fair, 3 = Good, 4 = Excellent. Based on the median rating of overall image quality across the three readers, the number of participants with each rating is reported for each scan. (NCT01618669)
Timeframe: Day 1 (rest MPI and stress MPI 1) and Day 2 - 15 (stress MPI 2)

,
Interventionparticipants (Number)
Rest MPI: ExcellentRest MPI: GoodRest MPI: FairRest MPI: PoorStress MPI 1: ExcellentStress MPI 1: GoodStress MPI 1: FairStress MPI 1: PoorStress MPI 2: ExcellentStress MPI 2: GoodStress MPI 2: FairStress MPI 2: Poor
Regadenoson After Peak Exercise140307910224287270192303430
Regadenoson Alone157308700211291330205293370

[back to top]

Target to Background Radiotracer Uptake Ratios From the First and Second Stress Scans

Image quality was assessed through radiotracer uptake in the heart (target organ) compared to liver, gut and combined liver plus gut (background interference). (NCT01618669)
Timeframe: Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)

,,,
Interventionratio (Mean)
Heart-to-LiverHeart-to-GutHeart-to-(Liver/Gut)
Regadenoson After Peak Exercise: MPI 11.051.121.02
Regadenoson After Peak Exercise: MPI 20.940.990.90
Regadenoson Alone: MPI 10.961.050.94
Regadenoson Alone: MPI 20.950.990.91

[back to top]

Proportion of Participants With Agreement in the Assessment of Absence or Presence of Ischemia Between First and Second Stress Scans

The number of segments with reversible defects was assessed by each of the 3 blinded independent expert readers. Based on the median count of the number of reversible defects across the 3 readers, categorized as absence (0 to 1 reversible segments) or presence (≥ 2 reversible defects) of ischemia, the proportion of participants with agreement in the presence and absence of ischemia between the first and second stress scans was calculated. (NCT01618669)
Timeframe: Day 1 (stress MPI 1) and Day 2 -15 (stress MPI 2)

Interventionproportion of participants (Number)
Regadenoson After Peak Exercise0.75
Regadenoson Alone0.77

[back to top]

Proportion of Participants With Agreement in the Assessment of Reversible Defects in 3 Categories of Ischemia Between First and Second Stress Scans

The number of segments with reversible defects was assessed by each of the 3 blinded independent expert readers. Based on the median count of the number of reversible defects across the 3 readers, categorized as 0 to 1, 2 to 4, or ≥ 5 reversible segments, the proportion of participants with agreement in the three ischemia categories between the first and second stress scans was to be calculated. In the reported data, these proportions only include the 0-1 and 2-4 categories; the ≥ 5 category was not included because there were no participants in this category for the Regadenoson Alone group for the initial stress MPI. (NCT01618669)
Timeframe: Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)

Interventionproportion of participants (Number)
Regadenoson After Peak Exercise0.73
Regadenoson Alone0.75

[back to top]

Proportion of Participants With Agreement in the Summed Stress Score (SSS) Between First and Second Stress Scans

"The 17-segment model for standardized myocardial segmentation was used to analyze MPI scans. Each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed:~0: normal perfusion~1: slightly reduced contrast/radiotracer uptake~2: moderately reduced contrast/radiotracer uptake~3: severely reduced contrast/radiotracer uptake~4: absent contrast/radiotracer uptake.~The Summed Stress Score (SSS) was calculated as the sum of the stress scores across the 17 segments. The mean value (rounded to the nearest integer) across the 3 readers was computed and the SSS was categorized into 4 group categorical variables based on the score: 0 to 3, 4 to 7, 8 to 11, and ≥ 12. The proportion of participants with agreement in respect to these categories between the two stress scans was calculated." (NCT01618669)
Timeframe: Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)

Interventionproportion of participants (Number)
Regadenoson After Peak Exercise0.86
Regadenoson Alone0.84

[back to top]

Proportion of Participants With Majority Reader Self-agreement in Ischemia Assessment Between First and Second Stress Scans

"SPECT scans were reviewed in a blinded fashion by 3 independent expert readers using the 17-segment model for standardized myocardial segmentation. At rest and stress, each segment was scored on a 0 (normal) to 4 (absent contrast/radiotracer uptake) scale by each of the 3 blinded readers according to the amount of contrast or radiotracer the myocardium in the segment absorbed. If the stress score was ≥ 2 and the rest score was less than the stress score, the segment was counted as having a reversible defect.~The number of segments with reversible defects was categorized as absence (0 - 1 reversible segments) or presence (≥ 2 defects reversible segments) of ischemia.~Each reader was defined as having self-agreement based upon identical categorization of a given participant as absent or present for ischemia for both the initial and second stress visits.~Majority agreement is if at least 2 out of the 3 blinded readers demonstrated self-agreement for a given participant." (NCT01618669)
Timeframe: Day 1 (rest scan and first stress scan) and Day 2 -15 (second stress scan)

Interventionproportion of participants (Number)
Regadenoson After Peak Exercise0.92
Regadenoson Alone0.95

[back to top]

Number of Participants With Adverse Events Within 24 Hours After Administration of Regadenoson

"An adverse event is considered serious if, in the view of either the investigator or sponsor, it results in any of the following outcomes:~Results in death,~Is life threatening,~Results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions,~Results in congenital anomaly, or birth defect,~Requires inpatient hospitalization or leads to prolongation of hospitalization~Other medically important events.~Relationship to study drug was assessed by the investigator." (NCT01618669)
Timeframe: Up to 24 hours after study drug administration for each stress MPI (Day 1 and Day 2-15)

,,,
Interventionparticipants (Number)
Any adverse eventDrug-related adverse eventDeathsSerious adverse eventsDrug-related serious adverse eventsAdverse events leading to discontinuationDrug-related AEs leading to discontinuation
Regadenoson After Peak Exercise: MPI 1302291052139
Regadenoson After Peak Exercise: MPI 231729802000
Regadenoson Alone: MPI 132931901055
Regadenoson Alone: MPI 232330801010

[back to top]

Participants With Less, the Same, or More Reversible Perfusion Defects Shown by the First Stress Scan When Compared to the Second Stress Scan

Each reader evaluated the initial stress SPECT MPI scan compared to the participant's second stress SPECT MPI scan (blinded at time of the evaluation) for whether there was Less (-1), the Same (0) or More (1) reversible perfusion defects. The median assessment of the 3 blinded readers was used to summarize the number of participants in each category. (NCT01618669)
Timeframe: Day 1 (stress MPI 1) and Day 2-15 (stress MPI 2)

,
Interventionparticipants (Number)
Less Reversible Perfusion DefectsSame Number of Reversible Perfusion DefectsMore Reversible Perfusion Defects
Regadenoson After Peak Exercise5744140
Regadenoson Alone4945927

[back to top]

Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity

The number of cardiac segments obscured by the sub-diaphragmatic activity by group by stress SPECT MPI scan and by reader is reported. (NCT01618669)
Timeframe: Day 1 (stress MPI 1) and Day - 15 (stress MPI 2)

,,,
Interventionpercentage of segments (Number)
Reader 1: Segment 1Reader 1: Segment 2Reader 1: Segment 3Reader 1: Segment 4Reader 1: Segment 5Reader 1: Segment 6Reader 1: Segment 7Reader 1: Segment 8Reader 1: Segment 9Reader 1: Segment 10Reader 1: Segment 11Reader 1: Segment 12Reader 1: Segment 13Reader 1: Segment 14Reader 1: Segment 15Reader 1: Segment 16Reader 1: Segment 17Reader 2: Segment 1Reader 2: Segment 2Reader 2: Segment 3Reader 2: Segment 4Reader 2: Segment 5Reader 2: Segment 6Reader 2: Segment 7Reader 2: Segment 8Reader 2: Segment 9Reader 2: Segment 10Reader 2: Segment 11Reader 2: Segment 12Reader 2: Segment 13Reader 2: Segment 14Reader 2: Segment 15Reader 2: Segment 16Reader 2: Segment 17Reader 3: Segment 1Reader 3: Segment 2Reader 3: Segment 3Reader 3: Segment 4Reader 3: Segment 5Reader 3: Segment 6Reader 3: Segment 7Reader 3: Segment 8Reader 3: Segment 9Reader 3: Segment 10Reader 3: Segment 11Reader 3: Segment 12Reader 3: Segment 13Reader 3: Segment 14Reader 3: Segment 15Reader 3: Segment 16Reader 3: Segment 17
Regadenoson After Peak Exercise: MPI 10.00.00.033.69.70.00.00.00.031.69.50.00.00.01.70.00.00.00.00.034.41.10.00.00.00.012.60.00.00.00.09.10.00.40.00.00.014.10.60.00.00.00.016.00.70.00.20.013.90.40.9
Regadenoson After Peak Exercise: MPI 20.00.00.037.28.40.00.00.00.035.58.20.00.00.00.90.00.00.00.00.035.10.40.00.00.20.011.90.20.00.00.08.70.20.00.20.00.016.70.40.00.00.00.017.80.20.00.00.013.80.70.9
Regadenoson Alone: MPI 10.00.00.034.27.90.00.00.00.032.37.50.00.00.02.40.20.00.00.20.232.50.70.00.00.00.413.80.60.00.00.010.50.00.00.00.00.017.90.70.00.00.00.018.50.60.00.00.013.10.40.7
Regadenoson Alone: MPI 20.00.00.037.47.70.00.00.00.036.37.50.00.00.02.10.20.00.00.00.632.50.70.00.00.00.413.10.20.00.00.09.50.00.00.00.00.017.20.20.00.00.00.018.90.20.00.00.014.60.20.6

[back to top]

Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events

"A clinically significant cardiac event is defined as:~Any of the following events found on the Holter electrocardiogram (ECG)/12-Lead ECG within 1 hour after regadenoson administration:~ventricular arrhythmias (sustained ventricular tachycardia, ventricular fibrillation, torsade de pointes, ventricular flutter),~ST-T depression (> 2 mm),~ST-T elevation (≥1 mm),~Atrioventricular (AV) block (2:1 AV block, AV Mobitz I, AV Mobitz II, complete heart block)~sinus arrest > 3 seconds in duration~Or~a treatment-emergent adverse event (TEAE) per the Medical Dictionary for Regulatory Activities (MedDRA) Standardised MedDRA Queries (SMQ) (Narrow Scope) for myocardial infarction~Or~a TEAE preferred term of angina unstable within 24 hours of regadenoson administration." (NCT01618669)
Timeframe: Within 1 hour for ECG events and up to 24 hours for adverse events after administration of regadenoson

,,,
Interventionpercentage of participants (Number)
Any EventAny Holter/12-Lead ECG AbnormalitySustained Ventricular TachycardiaVentricular Fibrillation or Ventricular FlutterTorsade de PointesST-T Depression (≥ 2 mm)ST-T Elevation (≥ 1 mm)2:1 AV BlockMobitz I Second Degree AV BlockMobitz II Second Degree AV BlockComplete Heart BlockPause > 3.0 secondsAny TEAE per SMQ for Myocardial InfarctionAcute Coronary SyndromeMyocardial InfarctionAdverse Event of Angina Unstable
Regadenoson After Peak Exercise: MPI 13.02.80.00.00.02.30.50.00.00.00.00.00.30.20.20.0
Regadenoson After Peak Exercise: MPI 20.90.90.00.00.00.60.40.00.00.00.00.00.00.00.00.0
Regadenoson Alone: MPI 10.50.50.00.00.00.40.20.00.00.00.00.00.00.00.00.0
Regadenoson Alone: MPI 20.40.40.00.00.00.40.00.00.00.00.00.00.00.00.00.0

[back to top]

Percentage of Scans With Subdiaphragmatic Interference

Each reader assessed the sub-diaphragmatic radiotracer interference with cardiac image quality using a 4-point scale of 0 = none, 1 = slight, 2 = moderate or 3 = severe for each stress SPECT MPI. The median rating across the 3 readers was used to summarize the percentage of scans with interference. (NCT01618669)
Timeframe: Day 1 (stress MPI 1) and Day 2 -15 (stress MPI 2)

,,,
Interventionpercentage of stress MPI scans (Number)
NoneSlightModerateSevere
Regadenoson After Peak Exercise: MPI 10.471.827.50.4
Regadenoson After Peak Exercise: MPI 20.063.736.30.0
Regadenoson Alone: MPI 10.068.131.50.4
Regadenoson Alone: MPI 20.067.432.60.0

[back to top]

Proportion of Participants With Agreement in the Summed Difference Score (SDS) Between First and Second Stress Scans

"The 17-segment model for standardized myocardial segmentation was used to analyze MPI scans. At rest and stress, each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed:~0: normal perfusion~1: slightly reduced contrast/ uptake~2: moderately reduced contrast/uptake~3: severely reduced contrast/uptake~4: absent contrast/uptake.~SSS was calculated as the sum of the stress scores across the 17 segments and the Summed Rest Score (SRS) was calculated as the sum of the rest scores across the 17 segments. The Summed Difference Score (SDS) is the difference in the SSS and SRS (SSS - SRS).~The mean value (rounded to the nearest integer) across the 3 readers was computed and the SDS was categorized into 3 categorical variables based on the score: 0 to 6, 7 to 13 and ≥ 14. The proportion of participants with agreement in respect to these categories between the two stress scans was calculated." (NCT01618669)
Timeframe: Day 1 (rest MPI and stress MPI 1) and Day 2 - 15 (stress MPI 2)

,,,,,
Interventionparticipants (Number)
MPI 1 SDS 0-6MPI 1 SDS 7-13MPI 1 SDS ≥ 14
REG Alone: MPI 2 SDS ≥ 14000
REG Alone: MPI 2 SDS 0-652720
REG Alone: MPI 2 SDS 7-13330
REG APEX: MPI 2 7-13430
REG APEX: MPI 2 SDS ≥ 14000
REG APEX: MPI 2 SDS 0-653100

[back to top]

Quantification of Myocardial Blood Volume

The investigators anticipated that a novel MRI imaging protocol using a high relaxivity blood-pool contrast agent (gadofosveset trisodium) would be capable of quantifying coronary flow reserve based on quantification of myocardial blood volume and would be correlated with myocardial flow reserve as measured in low spatial resolution nuclear SPECT scans. Pre- and post- gadofosveset trisodium images were to be used to calculate the myocardial blood volume. Myocardial blood volume is derived from an equation of the relaxation times of hydrogen atoms in the blood and myocardium. If the agent administered did not behave as a true intravascular agent in the myocardium, quantification of myocardial intravascular blood volume (and hence a calculated coronary flow reserve) could not be calculated using the specified approach. In this case, relaxation times would be reported. Relaxation (R) times are measured in inverse seconds. (NCT01655043)
Timeframe: outcome measured following single MRI scan

Interventionseconds^-1 (Mean)
Delta R1(blood)Delta R1(myo)
Coronary Artery Disease Patients3.631.23

[back to top]

Sensitivity of Regadenoson Stress-MRI for Detection of Coronary Artery Disease (CAD)

Determination of sensitivity of Regadenoson stress-MRI in the detection of CAD, using x-ray angiography as the standard. Perfusion images interpreted by three blinded readers as normal or abnormal; majority results of the three blinded readers are reported. (NCT01710254)
Timeframe: one MRI, up to 1 hour

InterventionPercentage of true positive cases (Number)
Regadenoson MRI80

[back to top]

Accuracy of Regadenoson Stress-MRI for Detection of Coronary Artery Disease (CAD)

Determination of accuracy of Regadenoson stress-MRI in the detection of CAD, using x-ray angiography as the standard. Accuracy is the percentage of correctly classified subjects (true positive + true negative) among all subjects (true positive + true negative + false positive + false negative). Perfusion images interpreted by three blinded readers as normal or abnormal; majority results of the three blinded readers are reported. (NCT01710254)
Timeframe: one MRI, up to 1 hour

InterventionPercentage of correct total cases (Number)
Regadenoson MRI96

[back to top]

Specificity of Regadenoson Stress-MRI for Detection of Coronary Artery Disease (CAD)

Determination of specificity of Regadenoson stress-MRI in the detection of CAD, using x-ray angiography as the standard. Perfusion images interpreted by three blinded readers as normal or abnormal; majority results of the three blinded readers are reported. (NCT01710254)
Timeframe: one MRI, up to 1 hour

InterventionPercentage of true negative cases (Number)
Regadenoson MRI100

[back to top]

Diagnostic Accuracy of Cardiac PET/MRI Examination

"The accuracy of the cardiac PET and cardiac MR examination components of the PET/MRI, and the accuracy of the combined PET/MR examination, for ischemic heart disease will be compared to the accuracy of cardiac SPECT in patients who have had ICA as truth or the reference standard. To assess the accuracy of an abbreviated PET/MR examination, an additional accuracy analysis was made using only the stress PET perfusion imaging and the MR LGE data sets. The accuracy of this combined data set was also determined with ICA as truth or the reference standard. Accuracy is calculated as % difference = (experimental - true) x 100%." (NCT01779869)
Timeframe: PET/MRI imaging was performed within 10 days after SPECT-MPI examination

Interventionpercentage (Number)
SPECT AccuracyMR AccuracyPET AccuracyCombined PET/MR AccuracyAbbreviated PET/MR
Single Group Assignment - Imaging5064616464

[back to top]

Level of Inflammatory Markers (IL-4)

To determine if regadenoson reduces levels of inflammatory markers among individuals with SCA and pain or ACS compared to placebo. (NCT01788631)
Timeframe: Baseline-End of study infusion over 48 hours

InterventionIL-4 levels as percent of baseline (Median)
Regadenoson Arm85.89
Placebo Arm100.91

[back to top]

Number of Participants With a Reduction in Invariant Natural-Killer T-Cell (iNKT Cell) Activation by 70% or More

To determine if infusional Regadenoson reduced iNKT cell activation among individuals with sickle cell anemia (SCA) and pain or acute chest syndrome (ACS) compared to placebo by 70% or greater. (NCT01788631)
Timeframe: Baseline-End of study infusion over 48 hours

InterventionParticipants (Count of Participants)
Regadenoson Arm21
Placebo Arm10

[back to top]

Number of Participants With an Improvement in Respiratory Symptoms

To determine if regadenoson improved respiratory symptoms among individuals with sickle cell anemia (SCA) and pain or acute chest syndrome (ACS) compared to placebo. Patients were classified as having an improvement in respiratory symptoms if they experienced any of the following outcomes:(1) respiratory rate decreased by 25% from baseline or normalized (≤20 bpm) or (2) degree of hypoxia (SpO2) on room air increased by 10% from baseline or normalized (≥92%) or (3) thoracic pain improved by 3 points from baseline on a 10-point visual analog scale. (NCT01788631)
Timeframe: Baseline-End of study infusion over 48 hours

InterventionParticipants (Count of Participants)
Regadenoson Arm10
Placebo Arm9

[back to top]

Opioid Use

To determine if regadenoson reduces opioid use among individuals with SCA and pain or ACS compared to placebo. (NCT01788631)
Timeframe: Baseline-End of study infusion over 48 hours

Interventionmg/kg/hr (Median)
Regadenoson Arm0.03
Placebo Arm0.04

[back to top]

Length of Hospital Stay

To determine if regadenoson reduces length of hospital stay among individuals admitted with SCA and pain or ACS compared to placebo (NCT01788631)
Timeframe: Hospital Presentation- Hospital Discharge, assessed up to 1 month

InterventionDays (Median)
Regadenoson Arm3.96
Placebo Arm3.99

[back to top]

Level of Inflammatory Markers (A2A)

To determine if regadenoson reduces levels of inflammatory markers among individuals with SCA and pain or ACS compared to placebo. (NCT01788631)
Timeframe: Baseline-End of study infusion over 48 hours

InterventionA2A levels as percent of baseline (Median)
Regadenoson Arm86.39
Placebo Arm100.95

[back to top]

Level of Inflammatory Markers (IFN-gamma)

To determine if regadenoson reduces levels of inflammatory markers among individuals with SCA and pain or ACS compared to placebo. (NCT01788631)
Timeframe: Baseline-End of study infusion over 48 hours

InterventionIFN-gamma levels as percent of baseline (Median)
Regadenoson Arm97.38
Placebo Arm105.66

[back to top]

All-cause Death

death from any cause (NCT01842035)
Timeframe: Until end of follow-up, median follow-up 40 months

InterventionParticipants (Count of Participants)
Heart Rate Response Greater Than Median8
Heart Rate Response Less Than Median8

[back to top]

All-cause Death or First Appropriate ICD Therapy

death or antitachycardia pacing therapy or shock for tachyarrhythmia determined by evaluation of the clinical information and by device diagnostics to be either ventricular fibrillation or ventricular tachycardia (NCT01842035)
Timeframe: Until end of follow-up, median follow-up 40 months

InterventionParticipants (Count of Participants)
Heart Rate Response Greater Than Median13
Heart Rate Response Less Than Median16

[back to top]

First Appropriate ICD Therapy

antitachycardia pacing therapy or shock for tachyarrhythmia determined by evaluation of the clinical information and by device diagnostics to be either ventricular fibrillation or ventricular tachycardia (NCT01842035)
Timeframe: Until end of follow-up, median follow-up 40 months

InterventionParticipants (Count of Participants)
Heart Rate Response Greater Than Median6
Heart Rate Response Less Than Median12

[back to top]

Inappropriate ICD Therapy

unnecessary antitachycardia pacing or shock delivered by the ICD for a rhythm that is not a true ventricular fibrillation or ventricular tachycardia (NCT01842035)
Timeframe: Until end of follow-up, median follow-up 40 months

InterventionParticipants (Count of Participants)
Heart Rate Response Greater Than Median3
Heart Rate Response Less Than Median2

[back to top]

Sudden Cardiac Death

Sudden cardiac death will be defined as death within 1 hour of symptom onset, or an unobserved death in which the patient was seen and known to be doing well within 24 hours of death. Survivors of aborted sudden cardiac death, resuscitated cardiac arrest, and those receiving appropriate ICD therapy will also be considered to have experienced sudden cardiac death and will be included in the primary end point. (NCT01842035)
Timeframe: Until end of follow-up, median follow-up 40 months

InterventionParticipants (Count of Participants)
Heart Rate Response Greater Than Median2
Heart Rate Response Less Than Median6

[back to top]

Sudden Cardiac Death or Appropriate ICD Therapy

Sudden cardiac death or antitachycardia pacing therapy or shock for tachyarrhythmia determined by evaluation of the clinical information and by device diagnostics to be either ventricular fibrillation or ventricular tachycardia (NCT01842035)
Timeframe: Until end of follow-up, median follow-up 40 months

InterventionParticipants (Count of Participants)
Heart Rate Response Greater Than Median8
Heart Rate Response Less Than Median15

[back to top]

Measure Quantitated Myocardial Perfusion Reserve After a 10 Second Delay in Lexiscan (Regadenoson)

The end-point of this study is to establish the mean and standard deviations of myocardial blood flow reserve (peak stress to rest ratio) values based on a 10 second, 1 minute, 2 minute and 4 minute delays between Lexiscan (Regadenoson) injection and the start of myocardial perfusion PET imaging. (NCT01919450)
Timeframe: 10 seconds

InterventionRatio (Median)
10 Second Delay2.34

[back to top]

Measure Quantitated Myocardial Perfusion Reserve After a 2 Minute Delay in Lexiscan (Regadenoson)

The end-point of this study is to establish the mean and standard deviations of myocardial blood flow reserve (peak stress to rest ratio) values based on a 10 second, 1 minute, 2 minute and 4 minute delays between Lexiscan (Regadenoson) injection and the start of myocardial perfusion PET imaging. (NCT01919450)
Timeframe: 2 mintues

InterventionRatio (Mean)
2 Minute Delay2.93

[back to top]

Measure Quantitated Myocardial Perfusion Reserve After a 4 Minute Delay in Lexiscan (Regadenoson)

The end-point of this study is to establish the mean and standard deviations of myocardial blood flow reserve (peak stress to rest ratio) values based on a 10 second, 1 minute, 2 minute and 4 minute delays between Lexiscan (Regadenoson) injection and the start of myocardial perfusion PET imaging. (NCT01919450)
Timeframe: 4 minutes

InterventionRatio (Mean)
4 Minute Delay2.57

[back to top]

Measure Quantitated Myocardial Perfusion Reserve After a 1 Minute Delay in Lexiscan (Regadenoson)

The end-point of this study is to establish the mean and standard deviations of myocardial blood flow reserve (peak stress to rest ratio) values based on a 10 second, 1 minute, 2 minute and 4 minute delays between Lexiscan (Regadenoson) injection and the start of myocardial perfusion PET imaging. (NCT01919450)
Timeframe: 1 minute

InterventionRatio (Mean)
1 Minute Delay2.76

[back to top]

Diagnostic Performance (Specificity and Sensitivity) for Detection of Myocardial Perfusion Deficits on Magnetic Resonance (MR) Images

In this study, the approach is to use nuclear myocardial perfusion (prior PET/SPECT scans for the enrolled patients) as the comparative standard for detection of myocardial ischemia (presence of perfusion deficits). Using this approach, the acquired MR images will be analyzed to determine the diagnostic performance (specificity and sensitivity) of the improved MRI technique for detection of myocardial perfusion deficits. (NCT01949844)
Timeframe: Baseline only

Interventionpercentage of true cases (Number)
diagnostic sensitivitydiagnostic specificity
Suspected Coronary Artery Disease (CAD)9594

[back to top]

Number of Participants With Detected Stress-induced Perfusion Abnormalities by 3D Analysis of MDCT Images

Perfusion defect on stress CT images obtained at peak effect of Regadenoson, in the presence of coronary stenosis >50%. (NCT01969916)
Timeframe: At least 1 year

InterventionParticipants (Count of Participants)
Regadenoson56

[back to top]

Late Gadolinium Enhancement and CIRCUMFERENTIAL Myocardial Strain

The Effects of the presence of LGE on CIRCUMFERENTIAL myocardial Strain (NCT02115308)
Timeframe: Day 1

,,
Interventionstrain (unitless) (Mean)
RESTREGADENOSON STRESSREST-to-STRESS
CONTROL-0.181-0.1690.012
LGE--0.139-0.150-0.011
LGE+-0.101-0.111-0.010

[back to top]

CIRCUMFERENTIAL STRAIN

"A measurement of the relative displacement of myocardial points directed along the circumference of the ventricular wall at a given radial distance from the left ventricular (LV) cavity center (e.g. midline). A normal circumferential strain is indicated by a negative decimal value and can be understood as the percentage shortening along the ventricular wall with a greater negative value indicating greater ventricular shortening along the circumference. A positive change in strain would therefore be interpreted as a decrease in circumferential shortening.~Because strain is a measurement in change in length (distance) divided by an original length (distance) it is considered unitless." (NCT02115308)
Timeframe: Day 1

,,
Interventionstrain (unitless) (Mean)
RESTREGADENSOSON STRESSREST-to-STRESS CHANGE
CAD_REMOTE-0.140-0.150-0.013
CAD_REVERSIBLE-0.121-0.126-0.006
CONTROL-0.181-0.1690.012

[back to top]

Late Gadolinium Enhancement (LGE) and RADIAL Myocardial Strain

"For each subject, the 16-segments were visually assessed along the short-axis plane for the presence of LGE. These images were collected post regadenoson stress recovery using an inversion-recovery prepared, fast gradient echo sequence and a delay of at least 8 minutes after administration of a single dose of gadobenate dimeglumine.~The presence of LGE within a segment is a separate classification of segment type. The segment classifications in the other outcomes are determined from the prior positron-emission-tomography (PET) examination where the LGE determination is based solely on cardiac magnetic resonance (CMR) imaging collected data.~The measurement was performed to determine if the presence of LGE within a particular segment affect the resulting strain?" (NCT02115308)
Timeframe: Day 1

,,
Interventionstrain (unitless) (Mean)
RESTREGADENOSON STRESSREST-to_STRESS
CONTROL0.1570.1900.032
LGE-0.1550.1850.031
LGE+0.1400.132-0.008

[back to top]

RADIAL STRAIN

"A measurement of the relative displacement between myocardial points between end-diastole and end-systole along a common ray extending from the center of the left ventricular (LV) cavity (analogous to myocardial thickening). A normal radial strain is indicated by a positive decimal value and can be understood as the percentage change in wall thickness of a myocardial segment. A POSITIVE change in radial strain indicates an increase in wall thickening.~Because strain is a measurement in change in length (distance) divided by an original length (distance) it is considered unitless." (NCT02115308)
Timeframe: Day 1

,,
Interventionunitless (strain) (Mean)
RESTREGADENOSON STRESSREST-to-STRESS CHANGE
CAD_REMOTE0.1490.1670.022
CAD_REVERSIBLE0.1500.141-0.009
CONTROL0.1580.1900.033

[back to top]

Change in AUC0-18 of the Temozolomide Concentration (AUC-T) in Brain Interstitium Before and After Regadenoson Infusion

The AUC-T for each day will be estimated by the trapezoid rule, based on the number of time points available for the particular evaluable patient. The PK variables will be tabulated and descriptive statistics calculated pre and post Regadenoson. The difference of AUCs will be summarized by mean and standard deviation or median and range if there is large variation from patient to patient. Means and standard deviation or mean and range will be presented for Cmax and AUC(inf) for each group. Graphic method will be used to display the difference for individual patient and all five patients. (NCT02389738)
Timeframe: 18 hours post temozolomide administration

Interventionpercentage of AUC (Mean)
Temozolomide alone AUC brain/plasmaTemozolomide/Regadenoson AUC brain/plasma
BBB Disruption With Regadenoson19.118.0

[back to top]

Coronary Flow Reserve

Rest and regadenoson stress coronary flow reserve by ammonia PET. Coronary flow calculated at rest and again at stress with coronary flow reserve calculated as the ratio of stress to rest coronary flow. (NCT02589977)
Timeframe: Baseline study visit

Interventionratio (Median)
Normal Participants2.64
Hypertensive Participants2.65
HFpEF Patients2.06

[back to top]

E/e' by Echo in Each Study Group.

E/e' by echo. E is the transmitral peak velocity in early diastole. e' is the early diastolic tissue Doppler velocity average between the septal and lateral mitral annulus. E/e' is the ratio of these two values. (NCT02589977)
Timeframe: Baseline study visit

Interventionratio (Median)
Normal Participants7.2
Hypertensive Participants8.2
HFpEF Patients13.0

[back to top]

Extracellular Volume (ECV) by CMR in Each Study Group

Extracellular volume (ECV) by CMR. (NCT02589977)
Timeframe: Baseline study visit

Interventionpercent ECV (Median)
Normal Participants31.9
Hypertensive Participants29.2
HFpEF Patients30.9

[back to top]

Oxidative Metabolism (Kmono/Rate Pressure Product) by PET in Each Study Group.

Oxidative metabolism (Kmono/rate pressure product) by PET. (NCT02589977)
Timeframe: Baseline study visit

Interventionmin-1/(beats/min x mmhg) (Median)
Normal Participants0.12
Hypertensive Participants0.09
HFpEF Patients0.09

[back to top]

Myocardial Perfusion Reserve by CMR in Each Study Group.

Myocardial perfusion reserve by CMR. (NCT02589977)
Timeframe: Baseline study visit.

Interventionratio (Median)
Normal Participants2.19
Hypertensive Participants1.74
HFpEF Patients1.29

[back to top]

Myocardial Perfusion Reserve

Myocardial perfusion reserve calculates the increase in myocardial perfusion after stress in comparison to rest. Outcome measure time frame specifies when the myocardial perfusion reserve was obtained in relation to date of heart-transplant for each patient. This was a one time measurement made after heart-transplantation. (NCT02597543)
Timeframe: Range of 1 to 12 years after heart transplantation for subjects and an average of 4 years after heart-transplantation.

Interventionarbitrary units (Mean)
Nonspecific Allograft Dysfunction1.52
Normal Graft Function1.94

[back to top]

Re-transplantation

Re-transplantation of the heart after enrollment (date of cardiac MRI). Measured 10 months after enrollment. (NCT02597543)
Timeframe: 10 months after enrollment (from date of cardiac MRI)

InterventionParticipants (Count of Participants)
Nonspecific Allograft Dysfunction0
Normal Graft Function0

[back to top] [back to top]

Late Gadolinium Enhancement

Late gadolinium enhancement demonstrates myocardial scar by cardiac MRI. This is measured the day of the cardiac MRI scan and is a one time measurement. Time frame is measurement of late gadolinium enhancement from date of heart-transplantation. (NCT02597543)
Timeframe: Range of 1 to 12 years after heart transplantation for subjects and an average of 4 years after heart-transplantation.

Interventionpercentage of myocardium (Mean)
Nonspecific Allograft Dysfunction5.7
Normal Graft Function1.8

[back to top]

Mean Segmental T1 Values of the Left Ventricle

T1 values are obtained at the time of the cardiac MRI and indicate the amount of myocardial edema. This was a one time measurement. Outcome measure time frame indicates when T1 values of the left ventricle were obtained in relation to heart-transplantation. (NCT02597543)
Timeframe: Range of 1 to 12 years after heart transplantation for subjects and an average of 4 years after heart-transplantation.

InterventionPercentage of myocardium (Mean)
Nonspecific Allograft Dysfunction44.5
Normal Graft Function38.1

[back to top]

Myocardial Ischemia/Infarction

Myocardial ischemia or infarct occurring from time of enrollment (when cardiac MRI performed) over subsequent 10 month period. (NCT02597543)
Timeframe: 10 months after enrollment (when cardiac MRI was performed)

InterventionParticipants (Count of Participants)
Nonspecific Allograft Dysfunction0
Normal Graft Function0

[back to top] [back to top]

Diagnostic Accuracy Using Quantitative Objective Image Quality Assessment

Assess the diagnostic accuracy of CT perfusion imaging compared to either SPECT or invasive angiography. (NCT03103061)
Timeframe: Immediately following CT perfusion imaging.

InterventionPercent (Number)
SensitivitySpecificityAccuracy
Standard Subject Enrollment85.770.675

[back to top]

Change From Baseline in Uncorrected Global Coronary Flow Reserve (CFR) at Week 4

Absolute change from baseline to Week 4 in uncorrected global CFR, as assessed by the central core laboratory. The global CFR is the ratio of absolute myocardial blood flow (MBF) at stress over that at rest. The MBF was assessed by 13N-ammonia or 82Rubidium positron emission tomography (PET) scan. (NCT03236311)
Timeframe: Baseline, Week 4

Interventionratio (Mean)
Placebo0.5
SAR4078990.2

[back to top]

CMR Measurement of Global Perfusion Reserve Ratio

"Comparison of the CMR measure of global perfusion reserve ratio (GPR) in each these patient groups.~In order to calculate this ratio, coronary sinus flow was measured twice:~prior to the the administration of adenosine/regadenoson~during the administration of adenosine/regadenoson" (NCT03249272)
Timeframe: The global perfusion ratio will be calculated from the measurements obtained at the time of the scan on Day 1 of the study.

Interventionratio (Median)
Hypertrophic Cardiomyopathy2.99
Non-ischemic Dilated Cardiomyopathy3.04
Control3.83

[back to top]

Prevalence of Microvascular Dysfunction (MVD) by a CMR Measurement of Whole-heart (Global) Perfusion Reserve Ratio in Patients With Hypertrophic Cardiomyopathy, Non-ischemic Cardiomyopathy, and Controls.

"Prevalence of microvascular dysfunction as determined by the CMR measure of global perfusion reserve ratio (GPR) in each these patient groups. MVD was considered present when either GPR was <2.0 or regional stress perfusion abnormalities were present.~In order to calculate this ratio, coronary sinus flow was measured twice:~prior to the the administration of adenosine/regadenoson~during the administration of adenosine/regadenoson~GPR is a ratio of coronary sinus flow during the administration adenosine/regadenoson divided by the baseline coronary sinus flow measured prior to the administration.~Regional perfusion abnormalities will be assessed at the time of adenosine/regadenoson administration." (NCT03249272)
Timeframe: The prevalence of MVD will be determined based on the findings at the time of the scan on Day 1 of the study.

InterventionPercentage of group with MVD (Number)
Hypertrophic Cardiomyopathy79
Non-ischemic Dilated Cardiomyopathy33.3
Control20

[back to top]

The Association Between Global Perfusion Reserve (GPR) Ratio and Regional Myocardial Scarring.

Relationship between global perfusion reserve ratio and regional myocardial scarring. (NCT03249272)
Timeframe: Both global perfusion ratio and the presence of regional scarring will be determined/measured from the images obtained during the scan on Day 1 of the study.

InterventionGlobal perfusion reserve ratio (Mean)
Hypertrophic Cardiomyopathy - Scarring3.19
Hypertrophic Cardiomyopathy - Without Scarring5.91
Non-ischemic Dilated Cardiomyopathy - Scarring3.16
Control - Without Scarring3.53

[back to top]